_pmid,_doi,_publicationTitle,_year,_toolName,_toolType,_usageType,publicationId,resourceId,usageId
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,spheroid culture system,advanced_cellular_models,Experimental Usage,PUB36730269,4f95c143-9441-51a0-ab5b-e8f5b7cdac0f,USE7223b586
PMID:40862755,10.3390/cells14161276,Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures.,,TAME chips,advanced_cellular_models,Experimental Usage,PUB40862755,14313702-6f1d-53aa-9e69-b743cca3438d,USE4cef23bc
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,3D rBM overlay model,advanced_cellular_models,Experimental Usage,PUB39061138,a2e8a2a7-8ca9-55f3-a360-83c729440728,USEfc6b5b32
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,cNF organoids,advanced_cellular_models,Development,PUB38744290,fa394cc7-9f63-5714-af1b-4240eaa62112,USE7b3a0948
PMID:31545171,10.7554/eLife.48983,Optical dopamine monitoring with dLight1 reveals mesolimbic phenotypes in a mouse model of neurofibromatosis type 1.,,129T2/SvEmsJ::C57Bl/6NTac Nf1+/- and Nf1+/+,animal_models,Experimental Usage,PUB31545171,9c816cb8-6187-5283-95bb-c35bca36e57a,USE62b54b5c
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,C57BL6/J Nf1+/−;Trp53+/−,animal_models,Experimental Usage,PUB32642734,92d2e667-6bf8-5dcc-9f16-9a6f2c08394a,USE883ac5d3
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 c.5425 C > T ; Arg1809Cys,animal_models,Experimental Usage,PUB35589737,59983fe4-e778-519b-b91e-eb1331dfc1ad,USEee32315c
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,R681X Nf1,animal_models,Experimental Usage,PUB35589737,4027ec9e-7379-583a-99a1-69db7e0df51e,USEe0d24e96
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 flox/flox ; Hoxb7-Cre,animal_models,Experimental Usage,PUB35589737,0e503f20-aacd-5634-a510-d313b55dc81f,USE454f25f1
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Nf1 f/neo ; hGFAP-Cre,animal_models,Experimental Usage,PUB35589737,32bf181d-ea22-556e-b56b-cc54d16a4ab7,USE64012ff3
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-IF,animal_models,Experimental Usage,PUB38216123,9ef4e72f-27a8-5a62-898e-da5059be3278,USE17b91ad5
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-PS,animal_models,Experimental Usage,PUB38216123,db1873f0-9852-563e-b595-a46452d0b540,USEc7739321
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,Nf1-IFPS,animal_models,Experimental Usage,PUB38216123,badc395b-6692-5782-b3e4-00d8fd731040,USE08e76506
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1(ob) (-/-),animal_models,Experimental Usage,PUB20200958,b7cbe81f-e9db-5fab-9564-521b0c878ecf,USE908d4c4a
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,2.3-kb α1(I) collagen-cre Nf1 flox/flox,animal_models,Experimental Usage,PUB20200958,56436cb7-cfed-5976-9200-23f810a66b9c,USE96e7bcdc
PMID:36890585 | PMID:40684195 | PMID:19191334 | PMID:21439418 | PMID:34935315 | PMID:25772366 | PMID:29847659 | PMID:29787563 | PMID:28525381 | PMID:25535838 | PMID:20200958,10.1186/s40478-023-01525-w | 10.1186/s40478-025-02075-z | 10.1002/glia.20845 | 10.1016/j.bone.2011.03.760 | 10.1117/1.JBO.26.12.125001 | 10.1016/j.celrep.2015.02.041 | 10.1167/iovs.17-22588 | 10.1371/journal.pone.0190001 | 10.18632/oncotarget.17589 | 10.7554/eLife.05151 | 10.1002/jbmr.42,Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. | Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Graph complexity analysis identifies an ETV5 tumor-specific network in human and murine low-grade glioma. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1. | Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1 flox/flox,animal_models,Experimental Usage,PUB820f2963,2433f01f-8ef3-514a-978a-93a449dcc8b4,USE16e3b840
PMID:33078583 | PMID:21681782 | PMID:21551250 | PMID:21726432 | PMID:32839340 | PMID:18242513,10.1002/jcsm.12632 | 10.1002/ajh.22035 | 10.1158/0008-5472.CAN-10-4577 | 10.1186/1741-7015-9-82 | 10.1073/pnas.2008391117 | 10.1016/j.ccr.2008.01.003,Cell autonomous requirement of neurofibromin (Nf1) for postnatal muscle hypertrophic growth and metabolic homeostasis. | Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype. | Susceptible stages in Schwann cells for NF1-associated plexiform neurofibroma development. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1. | Brain-wide structural and functional disruption in mice with oligodendrocyte-specific | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,Nf1 flox,animal_models,Experimental Usage,PUB76829018,ba5ab76b-b23e-5258-9d61-886f4ab09510,USEf02486d3
PMID:32781282 | PMID:21199799 | PMID:8582272 | PMID:21949590 | PMID:40590220 | PMID:36890585 | PMID:40684195 | PMID:23071067 | PMID:26190969 | PMID:21439418 | PMID:25772366 | PMID:29847659 | PMID:18242513 | PMID:28525381 | PMID:16835260 | PMID:18632543,10.1016/j.trsl.2020.08.001 | 10.1158/0008-5472.CAN-10-2732 | 10.1242/dev.121.11.3583 | 10.2478/v10134-010-0025-8 | 10.1172/JCI188932 | 10.1186/s40478-023-01525-w | 10.1186/s40478-025-02075-z | 10.1158/0008-5472.CAN-12-1728 | 10.3389/fncel.2015.00234 | 10.1016/j.bone.2011.03.760 | 10.1016/j.celrep.2015.02.041 | 10.1167/iovs.17-22588 | 10.1016/j.ccr.2008.01.003 | 10.18632/oncotarget.17589 | 10.1093/hmg/ddl165 | 10.1001/jama.300.3.287,"Nf1 heterozygous mice recapitulate the anthropometric and metabolic features of human neurofibromatosis type 1. | Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice. | Neurofibromin-deficient fibroblasts fail to form perineurium in vitro. | ALTERED CALCIUM CURRENTS AND AXONAL GROWTH IN Nf1 HAPLOINSUFFICIENT MICE. | A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Neurofibromatosis type 1-dependent alterations in mouse microglia function are not cell-intrinsic. | Unraveling the development of cutaneous neurofibromas in neurofibromatosis type 1. | Genetically mediated Nf1 loss in mice promotes diverse radiation-induced tumors modeling second malignant neoplasms. | In vivo synaptic transmission and morphology in mouse models of Tuberous sclerosis, Fragile X syndrome, Neurofibromatosis type 1, and Costello syndrome. | Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation. | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. | Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial.",,Nf1+/-,animal_models,Experimental Usage,PUB51363032,9c821f99-a92d-5fcc-b512-8607480ae168,USE69442b09
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,y w Mer4,animal_models,Experimental Usage,PUB24595234,ce320a62-9c23-56c1-a31e-86a5bd53bbb8,USE4ad67f29
PMID:24595234,10.1371/journal.pone.0090853,In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,4/FM7; T80-Gal4 y w Mer4,animal_models,Experimental Usage,PUB24595234,b1c5c572-3b5c-52a6-a910-33321c4f1828,USEd4ac9002
PMID:30479396,10.1038/s41467-018-07452-y,NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation.,,PLP CreERT2; Nf1 f/−; ROSA-LacZ,animal_models,Experimental Usage,PUB30479396,64c128f0-d5ad-571d-a6d2-4a466d982210,USE953cb54b
PMID:34935315 | PMID:24465906 | PMID:21726432,10.1117/1.JBO.26.12.125001 | 10.1371/journal.pone.0086115 | 10.1186/1741-7015-9-82,"Analysis of muscle tissue in vivo using fiber-optic autofluorescence and diffuse reflectance spectroscopy. | Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1. | MIA is a potential biomarker for tumour load in neurofibromatosis type 1.",,Nf1Prx1-/-,animal_models,Experimental Usage,PUBad11fce9,d6ef2a65-bc56-578e-a426-a8e42388839b,USEe702e5a4
PMID:21963652 | PMID:19191334 | PMID:23225063 | PMID:25772366,10.1016/j.expneurol.2011.09.005 | 10.1002/glia.20845 | 10.1002/ana.23793 | 10.1016/j.celrep.2015.02.041,PET imaging for attention deficit preclinical drug testing in neurofibromatosis-1 mice. | Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation. | Dopamine deficiency underlies learning deficits in neurofibromatosis-1 mice. | Mouse low-grade gliomas contain cancer stem cells with unique molecular and functional properties.,,Nf1+/− GFAP CKO,animal_models,Experimental Usage,PUBa1435977,edade01d-5b28-5d39-b592-a2355cac456a,USE9ddffd20
PMID:21439418,10.1016/j.bone.2011.03.760,Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model.,,Nf1(flox/-);Col2.3Cre(+),animal_models,Development,PUB21439418,359e011a-d18d-5ec9-9e8b-1b264e17c46c,USEb1691f85
PMID:38502231 | PMID:34010628,10.1172/JCI176748 | 10.1016/j.stem.2021.04.029,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,cisNP,animal_models,Experimental Usage,PUB7ceede6d,866607df-5a44-5eae-9b1e-8d6411ecb745,USE7c8422d8
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,y [1] sc[*] v [1] sev [21]; P{y[+t7.7] v[+t1.8] = TKO.GS01796}attP40,animal_models,Experimental Usage,PUB39129390,38365203-9446-583d-a77b-e07fb3a87d2b,USE460e3b8c
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,P{ KK101909 }VIE‐260B,animal_models,Experimental Usage,PUB39129390,06ff776b-fea8-54f5-b727-9abca4ce187d,USEd9d6d4ea
PMID:30571760,10.1371/journal.pone.0208835,Neurofibromin haploinsufficiency results in altered spermatogenesis in a mouse model of neurofibromatosis type 1.,,Nf1Dsk9/+,animal_models,Experimental Usage,PUB30571760,40599842-43f7-5565-b886-5dc649e0d30d,USEc043fbbf
PMID:29408605,10.1016/j.neuroscience.2018.01.054,Nf2 Mutation in Schwann Cells Delays Functional Neural Recovery Following Injury.,,P0SchΔ39-121,animal_models,Experimental Usage,PUB29408605,b25925a3-6f19-5e5b-be0c-42a0782b9c79,USEa2b8dd36
PMID:38931352,10.3390/ph17060685,PET Imaging of Neurofibromatosis Type 1 with a Fluorine-18 Labeled Tryptophan Radiotracer.,,"Trp53, Nf1, Suz12 triple mutant",animal_models,Experimental Usage,PUB38931352,5eb80e47-0cdb-5b04-ba4d-98e4c6d6a91c,USE33ec900f
PMID:33442015 | PMID:31527226 | PMID:33658640 | PMID:38127282,10.1038/s41591-020-01193-6 | 10.1158/1535-7163.MCT-19-0123 | 10.1038/s41416-021-01270-8 | 10.1158/1078-0432.CCR-23-2548,"Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Ketotifen Modulates Mast Cell Chemotaxis to Kit-Ligand, but Does Not Impact Mast Cell Numbers, Degranulation, or Tumor Behavior in Neurofibromas of | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.",,Nf1flox/flox;PostnCre,animal_models,Experimental Usage,PUB69ba4f7d,b28a9b9d-7cad-566a-af24-fabd2d1c9444,USE3e7b5dac
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,NF1 fl/fl Tp53 fl/fl Eed fl/fl;Dhh-Cre,animal_models,Experimental Usage,PUB36322658,cba9e7f2-5307-57c3-a000-be83339d7221,USEa1609eeb
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1 R1947/+,animal_models,Development,PUB37520682,9f90706d-5b59-553d-9743-1eb6dbc61c5d,USEf08d1362
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,Nf1fl/fl,animal_models,Experimental Usage,PUB34040258,c910dd12-e034-5ad1-bad3-44c6b4b96de6,USE7c7cbd03
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,OPG Nf1fl/mut (Nf1+/−),animal_models,Experimental Usage,PUB34040258,03d2ffe3-ea87-5e39-894c-adc7cb5da85d,USE235d47c2
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 hGFAP CKO,animal_models,Experimental Usage,PUB22901811,8948e47d-3bbf-5cb8-ba55-74c15a4f3e96,USE7c4b5b58
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 NcreER CKO,animal_models,Experimental Usage,PUB22901811,a4552f3c-0475-5da9-81fa-9e9b89c1b6a0,USE7b86486c
PMID:21681782,10.1002/ajh.22035,Nf1 mutant mice with p19ARF gene loss develop accelerated hematopoietic disease resembling acute leukemia with a variable phenotype.,,Nf1 fcr,animal_models,Experimental Usage,PUB21681782,cb2faad8-e4ab-54ab-9286-f4f4544b40f5,USEbe1b1ce6
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,NPcis,animal_models,Experimental Usage,PUB36730269,f8ad311d-5503-5185-8331-bb3622c60dda,USEde9653c8
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,"Nf1 flox/mut; GFAP-Cre, Nf1+/− GFAP CKO",animal_models,Experimental Usage,PUB20554030,66988b6a-7f49-5b92-b5cf-58db189fc582,USEa6e58b8f
PMID:41444363,10.1038/s41598-025-32031-9,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model.,,Postn-Cre; Nf2flox/flox,animal_models,Experimental Usage,PUB41444363,912ab836-55cc-5769-bab0-ad1201b989f4,USE97ef063a
PMID:41444363 | PMID:24817309 | PMID:17924978 | PMID:38945076,10.1038/s41598-025-32031-9 | 10.1371/journal.pone.0097320 | 10.1111/j.1750-3639.2007.00105.x | 10.1016/j.redox.2024.103249,Focused ultrasound-mediated drug delivery of bevacizumab in treating NF2-related schwannomatosis in an animal model. | Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner. | Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation.,,Nf2flox/flox,animal_models,Experimental Usage,PUBd78d35d1,95087676-d95f-5986-8a19-a7491d31d4f7,USE05a39e1b
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,"Dhh::Cre, Nf1fl/fl, Pten",animal_models,Experimental Usage,PUB41036607,f5cbd630-c2a5-5c55-8dd6-7db2cda555e9,USEd16cef53
PMID:21216928 | PMID:26883872 | PMID:20551058,10.1158/1535-7163.MCT-10-0654 | 10.1016/j.jprot.2016.02.004 | 10.1158/0008-5472.CAN-09-3769,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes. | 3-D imaging mass spectrometry of protein distributions in mouse Neurofibromatosis 1 (NF1)-associated optic glioma. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Nf1 flox/flox; GFAP-Cre,animal_models,Experimental Usage,PUBff6e5d17,4a5e5e77-eb10-5cbf-bc35-521ffdda67f4,USEeb7a22d4
PMID:28029918,10.1056/NEJMoa1605943,Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.,,DhhCre;Nf1fl/fl,animal_models,Experimental Usage,PUB28029918,58b5ecc6-5290-5dc9-aa53-358a7a70fad1,USE263e15ab
PMID:24465906,10.1371/journal.pone.0086115,"Multiscale, converging defects of macro-porosity, microstructure and matrix mineralization impact long bone fragility in NF1.",,Nf1Col1,animal_models,Experimental Usage,PUB24465906,bd9636e4-d1b2-5181-a19b-29cd24f4f64d,USEc3b6774a
PMID:28256556 | PMID:26904939,10.1038/srep43315 | 10.1016/j.celrep.2016.01.074,An inflammatory gene signature distinguishes neurofibroma Schwann cells and macrophages from cells in the normal peripheral nervous system. | Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,Nf1fl/fl;DhhCre,animal_models,Experimental Usage,PUB8758ff08,d835ef05-a6e7-5269-adec-43e288108932,USE0a789228
PMID:26904939,10.1016/j.celrep.2016.01.074,Insertional Mutagenesis Identifies a STAT3/Arid1b/β-catenin Pathway Driving Neurofibroma Initiation.,,Stat3(fl/fl);Nf1(fl/fl);DhhCre,animal_models,Experimental Usage,PUB26904939,5ad65882-986b-5a72-86a2-69e3b6d8a5c6,USE7b2959a7
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Nf1f/f;Trp53f/f;Nes-TK,animal_models,Experimental Usage,PUB34010628,019086d3-2877-507f-946f-4a350906b3c5,USEff66b6af
PMID:34010628,10.1016/j.stem.2021.04.029,Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.,,Nf1f/f;Trp53f/f;CGD,animal_models,Experimental Usage,PUB34010628,22f30826-2dc3-5a19-a9b6-22427fdbcd0b,USE05a596dd
PMID:18242513,10.1016/j.ccr.2008.01.003,The loss of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest stem cells.,,Nf1/p53-/-,animal_models,Experimental Usage,PUB18242513,3f1d08b5-7f28-5444-b71f-adb4546b3066,USE3ec7523c
PMID:25917366,10.1038/mp.2015.48,HCN channels are a novel therapeutic target for cognitive dysfunction in Neurofibromatosis type 1.,,9a−/9a− Nf1,animal_models,Experimental Usage,PUB25917366,ac709e73-9f67-5ce8-9835-bd64d2f50993,USEc41d9803
PMID:17924978,10.1111/j.1750-3639.2007.00105.x,Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.,,Nf2 flox2/flox2 ;p16 Ink4a*/*,animal_models,Experimental Usage,PUB17924978,a0443d94-cf21-5ff9-bea5-10c21c67b6e7,USE229824ed
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,H7;Nf1mut,animal_models,Experimental Usage,PUB37140985,f03b3b12-dc42-540a-8105-3147d425fb1f,USE0da1cfca
PMID:24375753 | PMID:20551058 | PMID:28525381,10.1002/ana.24093 | 10.1158/0008-5472.CAN-09-3769 | 10.18632/oncotarget.17589,Sex Is a major determinant of neuronal dysfunction in neurofibromatosis type 1. | Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1. | The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut;GFAP-Cre,animal_models,Experimental Usage,PUB8087f428,3a865aff-eb92-5ed3-a87b-6ccc9db254fe,USEb7686259
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,DhhCre,animal_models,Experimental Usage,PUB38127282,b8f5e9c2-6b81-5c2b-bc67-44eaa3d0cc72,USE868ec6be
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,Nf1flox/flox;Arf flox/flox;PostnCre+,animal_models,Experimental Usage,PUB38127282,6303a527-7a77-5149-a18b-479f76908051,USEad75793d
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/wt,animal_models,Experimental Usage,PUB28525381,5ffaafc6-5cfc-5ef4-b3fd-e89ad69b4560,USE1b40e576
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut,animal_models,Experimental Usage,PUB28525381,1bd5aaf0-4cc3-592c-897a-9e801384b9b6,USEdfb9d814
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/flox; Olig2-Cre,animal_models,Experimental Usage,PUB28525381,c1738be3-7190-5eed-8f1e-44c26b7840cf,USE444af014
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut; Olig2-Cre,animal_models,Experimental Usage,PUB28525381,72b463a4-9450-5933-9ee9-144f93c2e642,USEaddbdcb8
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/flox; Prom1-CreER,animal_models,Experimental Usage,PUB28525381,9831ac31-0d36-5fac-9acf-a05868bb41cf,USEe96054b6
PMID:28525381,10.18632/oncotarget.17589,The cell of origin dictates the temporal course of neurofibromatosis-1 (Nf1) low-grade glioma formation.,,Nf1flox/mut; Prom1-CreER,animal_models,Experimental Usage,PUB28525381,c4168bda-acf2-50c3-b7a4-adf9290dab55,USE12885d7e
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl,animal_models,Experimental Usage,PUB36148553,680350a0-4047-53d0-a656-b2023afec10d,USE826fcb26
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl YAP fl/fl,animal_models,Experimental Usage,PUB36148553,2db4c5f8-aa40-5224-8496-b01342a63231,USE6022176e
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Periostin-CRE;NF2 fl/fl TAZ fl/fl,animal_models,Experimental Usage,PUB36148553,707cc2cc-7915-5ee8-8ff5-909b0be068fd,USE27d228d6
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,P0-CRE,animal_models,Experimental Usage,PUB36148553,6aed20e7-7783-549b-8c58-ba167a441fdc,USE6c016cdd
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Postn-cre;Nf2f/f,animal_models,Experimental Usage,PUB32438526,2b37cdeb-3836-52bd-a2a5-a229d9b507b0,USEbc22d825
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,DhhCre;Nf1f/f;Luciferase,animal_models,Experimental Usage,PUB40723243,2f569e31-8ff7-54e8-b684-176b4df47f50,USE05a19618
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,Tg(U6x:nf2a/b-4sgRNA),animal_models,Development,PUB39415595,40149ff0-d3d4-5803-bd93-aa74eca79655,USE11028e7a
PMID:33978635,10.1093/noajnl/vdab020,Selumetinib normalizes Ras/MAPK signaling in clinically relevant neurofibromatosis type 1 minipig tissues in vivo.,,NF1 R1947X minipig,animal_models,Development,PUB33978635,2f1c5933-8ac9-5f7d-a7e1-60f4eded55c2,USE6682d3f2
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,TetOff-Osx-/-Nf1,animal_models,Experimental Usage,PUB25043591,61dad128-c400-5e13-b462-a5c01a5644b6,USEd96ff346
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Osx-/-Nf1flox/flox,animal_models,Experimental Usage,PUB25043591,61ef5af3-9ee1-551b-a8d2-4b6cbee11331,USEbfc8af71
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,"Osx-tTA,tetO-cre;Nf1flox/flox",animal_models,Experimental Usage,PUB25043591,4f21943c-ea3d-5020-849d-053e3e34536c,USE7576fece
PMID:24371224,10.1158/0008-5472.CAN-13-2062,Tumor suppressor alterations cooperate to drive aggressive mesotheliomas with enriched cancer stem cells via a p53-miR-34a-c-Met axis.,,Nf2+/-,animal_models,Experimental Usage,PUB24371224,54f66d81-ea33-5c3e-b5c9-763b915539d1,USE75b8aea4
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,hGFAP-cre,animal_models,Experimental Usage,PUB25535838,f3355321-fa18-5f7e-8f14-d892385d821a,USE642ea09d
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Math1-cre,animal_models,Experimental Usage,PUB25535838,fdfe318a-0b2d-54d2-87e4-66a0f4e6ad04,USE34e227f7
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,L7-cre,animal_models,Experimental Usage,PUB25535838,b9bf1586-64f3-584d-ac39-70ab47e7832d,USEa1b13642
PMID:25535838,10.7554/eLife.05151,Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,Nestin-creER,animal_models,Experimental Usage,PUB25535838,cd685fab-cc29-5bfc-bb21-77237036daeb,USE18334cd1
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,Nf1-Arf flox/flox ;Postn-Cre,animal_models,Experimental Usage,PUB33658640,0a5050bc-6f25-584d-94ef-06f1f9dd8eb0,USEd2b40d4b
PMID:38216123 | PMID:38481529 | PMID:37446790 | PMID:39890807 | PMID:29438698 | PMID:29847659 | PMID:36241865,10.1016/j.molmet.2024.101876 | 10.3389/fcell.2024.1359561 | 10.3390/molecules28135128 | 10.1038/s41598-024-84493-y | 10.1016/j.ccell.2018.01.005 | 10.1167/iovs.17-22588 | 10.1038/s12276-022-00850-9,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Neurofibromin Deficiency Induces Endothelial Cell Proliferation and Retinal Neovascularization. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,neurofibromin,antibodies,Experimental Usage,PUB25df4dd2,d724a5d6-8188-536b-bb02-0fc5744ff9e6,USE0373599f
PMID:32457840 | PMID:20195187 | PMID:21072183 | PMID:31015291 | PMID:28126595 | PMID:29715273 | PMID:30274821 | PMID:39415595 | PMID:38945076 | PMID:24595234,10.3389/fonc.2020.00687 | 10.1097/MAO.0b013e3181d2777f | 10.1371/journal.pone.0013791 | 10.1126/scisignal.aau8749 | 10.1016/j.ebiom.2017.01.020 | 10.1371/journal.pone.0196726 | 10.1016/j.ebiom.2018.09.042 | 10.1242/dmm.050862 | 10.1016/j.redox.2024.103249 | 10.1371/journal.pone.0090853,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling. | Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis. | p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b. | Selective nitration of Hsp90 acts as a metabolic switch promoting tumor cell proliferation. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.",,Merlin,antibodies,Experimental Usage,PUB935bfae1,a18d6751-6837-5aa9-bc05-2697d979a999,USE1ecb3ade
PMID:41022755 | PMID:28166733 | PMID:38714355 | PMID:39472976 | PMID:41564118 | PMID:30479396 | PMID:39129390 | PMID:34257279 | PMID:34011935 | PMID:25535838,10.1038/s41467-025-63619-4 | 10.1186/s12864-017-3519-7 | 10.1158/1535-7163.MCT-23-0510 | 10.1186/s40478-024-01875-z | 10.1371/journal.pone.0340183 | 10.1038/s41467-018-07452-y | 10.1002/1878-0261.13704 | 10.1038/s41467-021-24505-x | 10.1038/s41419-021-03802-9 | 10.7554/eLife.05151,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma. | NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | NF1 heterozygosity fosters de novo tumorigenesis but impairs malignant transformation. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Neurofibromin regulates metabolic rate via neuronal mechanisms in Drosophila. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Transient inhibition of the ERK pathway prevents cerebellar developmental defects and improves long-term motor functions in murine models of neurofibromatosis type 1.,,NF1,antibodies,Experimental Usage,PUB34bef85d,d99bdc9f-6321-5c0a-b270-e41d89d883b0,USE5a374805
PMID:19191334,10.1002/glia.20845,Microarray analyses reveal regional astrocyte heterogeneity with implications for neurofibromatosis type 1 (NF1)-regulated glial proliferation.,,NF1GRP-D,antibodies,Experimental Usage,PUB19191334,78627244-ee2f-5a10-8bb6-87e12f15e74f,USE44867ab4
PMID:33273014 | PMID:38216572 | PMID:19144871,10.1074/jbc.RA120.014960 | 10.1038/s41467-024-44755-9 | 10.3181/0809-RM-275,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,NF2/merlin,antibodies,Experimental Usage,PUB16e2956c,583fc9c4-ef58-5741-978d-ffdea11fbd88,USE2b98597a
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,Drosophila neurofibromin,antibodies,Experimental Usage,PUB39129390,e81f19f7-1813-5ec5-b1f3-4a2add294e96,USE47d941ac
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,human neurofibromin,antibodies,Experimental Usage,PUB39129390,4021a726-e62c-5ac9-bd49-294673a4204b,USEc4962954
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,phospho-Merlin,antibodies,Experimental Usage,PUB28126595,dbdf1ca3-bf76-5dcf-a6c1-188565ac5a5c,USE2cfda85f
PMID:29715273 | PMID:26219339,10.1371/journal.pone.0196726 | 10.18632/oncotarget.4858,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,NF2,antibodies,Experimental Usage,PUB50430a7b,0f8afde2-7213-5154-95dd-2d492c56adcc,USE8c895ca1
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,phospho S518-Merlin,antibodies,Experimental Usage,PUB29715273,b09845f4-970f-571a-8e0c-e6c8b93e94da,USE6b25a06c
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,neurofibromin/NF1,antibodies,Experimental Usage,PUB40590220,b3a57db0-d64e-5b53-8556-a3bfc93f6f5b,USE773836b5
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,neurofibromin 1,antibodies,Experimental Usage,PUB41036607,94972c11-296d-52a8-ad10-d805b5b59ff4,USE99d94341
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,SUZ12,antibodies,Experimental Usage,PUB28166733,dd40dcb1-e7b5-5164-8751-dfb0daa65243,USE33b1d526
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,S518-Merlin,antibodies,Experimental Usage,PUB25043298,1b15c6e8-036c-5237-a331-13de48f550e9,USE514b1949
PMID:32642734,10.1093/noajnl/vdz026,Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1.,,NPcis cell line,cell_lines,Experimental Usage,PUB32642734,41f3ec49-a3df-56a8-be13-329fac246519,USE20dce609
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,BJFF.6,cell_lines,Experimental Usage,PUB35589737,3dc7da7a-91d2-56ae-af93-c1cea07d24a4,USE0467cf9f
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,Normal human Schwann cells (Sciencell),cell_lines,Experimental Usage,PUB35589737,0e0df540-0cd5-5dcc-863f-c5726016888b,USE4d3d7f6b
PMID:12057013,10.1186/1471-2164-3-13,Complex splicing pattern generates great diversity in human NF1 transcripts.,,TOP-10F' cells,cell_lines,Experimental Usage,PUB12057013,90ede777-afc9-5311-b681-ce6333eae4cb,USE8e881073
PMID:38216123 | PMID:40507334,10.1016/j.molmet.2024.101876 | 10.3390/cancers17111852,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer. | Development of a Novel Biomarker Platform for Profiling Key Protein-Protein Interactions to Predict the Efficacy of BH3-Mimetic Drugs.,,MCF7,cell_lines,Experimental Usage,PUB75cf961f,7009c225-cd7f-57a0-adb2-d1a86b112043,USEe662681c
PMID:20200958,10.1002/jbmr.42,Local low-dose lovastatin delivery improves the bone-healing defect caused by Nf1 loss of function in osteoblasts.,,Nf1 flox/flox calvaria osteoblasts,cell_lines,Experimental Usage,PUB20200958,2161e9dc-dc78-5518-a26b-b35422575e49,USEbf743cfb
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,DH10Bac cells,cell_lines,Experimental Usage,PUB31836666,7750e324-2e59-5cb7-ba9a-71dc007bf88d,USE511ac279
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,BL21(DE3),cell_lines,Experimental Usage,PUB31836666,c3833025-8a17-54ac-a1ec-57c9531dd2ce,USE25fe230e
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Sf9 cells,cell_lines,Experimental Usage,PUB31836666,5d82da91-d47d-578b-9ce7-5bce5028b878,USE28a9212b
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,Tni-FNL cells,cell_lines,Experimental Usage,PUB31836666,295395e8-095c-58b4-bd92-9b5178a341a4,USEfdb8d8d4
PMID:31836666,10.1074/jbc.RA119.010934,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer.,,NF1-null HEK293T cell line,cell_lines,Development,PUB31836666,0b3cb4ca-5e44-5145-babc-2b10416795c8,USEb518f376
PMID:40590220 | PMID:35789380 | PMID:31836666 | PMID:29402968 | PMID:31015291 | PMID:40225167 | PMID:34415582 | PMID:39269317 | PMID:23175151 | PMID:38216587 | PMID:20554030 | PMID:28166733 | PMID:33934112,10.1172/JCI188932 | 10.1158/2159-8290.CD-21-1671 | 10.1074/jbc.RA119.010934 | 10.1038/s41598-018-20894-0 | 10.1126/scisignal.aau8749 | 10.1155/2023/9628049 | 10.1002/glia.24075 | 10.1158/1078-0432.CCR-24-1750 | 10.1038/bjc.2012.518 | 10.1038/s41467-023-40408-5 | 10.1016/j.jneuroim.2010.05.002 | 10.1186/s12864-017-3519-7 | 10.1038/s41419-021-03716-6,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. | Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies. | Proximity biotinylation identifies a set of conformation-specific interactions between Merlin and cell junction proteins. | Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome. | Notch signaling via Hey1 and Id2b regulates Müller glia's regenerative response to retinal injury. | MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. | A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia.,,HEK293T cells,cell_lines,Experimental Usage,PUB8eeda84c,6ba75f31-1687-55b8-a135-05638c896b67,USE26eb8bde
PMID:38201517 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:41036607 | PMID:38203448 | PMID:23535903,10.3390/cancers16010089 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1158/1535-7163.MCT-24-1053 | 10.3390/ijms25010277 | 10.1158/2159-8290.CD-13-0081,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,S462TY,cell_lines,Experimental Usage,PUB4ea68a68,906fc06b-68d4-5355-ae14-f8a175ea9cb3,USE23b516fc
PMID:38201517 | PMID:18367665,10.3390/cancers16010089 | 10.1124/jpet.107.135830,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,iSC,cell_lines,Experimental Usage,PUB7b6d47c3,33501856-51de-5bac-813a-6461cff1afde,USEdc9511fb
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,A549,cell_lines,Experimental Usage,PUB38201517,e2918a1d-a7d4-5193-a0f5-248ecba5c0af,USE43e178d0
PMID:38201517 | PMID:41022755 | PMID:39269317 | PMID:18367665 | PMID:37246765 | PMID:33658640 | PMID:24824755 | PMID:39129390 | PMID:18413802 | PMID:24681606 | PMID:23685747 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38127282 | PMID:38216572 | PMID:38203448 | PMID:23535903 | PMID:41036607 | PMID:33032988,10.3390/cancers16010089 | 10.1038/s41467-025-63619-4 | 10.1158/1078-0432.CCR-24-1750 | 10.1124/jpet.107.135830 | 10.1093/neuonc/noad097 | 10.1038/s41416-021-01270-8 | 10.1371/journal.pone.0096733 | 10.1002/1878-0261.13704 | 10.1158/1535-7163.MCT-07-0518 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548 | 10.1038/s41467-024-44755-9 | 10.3390/ijms25010277 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-24-1053 | 10.1158/0008-5472.CAN-20-1365,"Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers. | Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.",,ST88-14,cell_lines,Experimental Usage,PUBe87ca157,733801bc-7188-503b-8116-384c9879b9f3,USEa42d3652
PMID:38201517,10.3390/cancers16010089,Synergistic Suppression of NF1 Malignant Peripheral Nerve Sheath Tumor Cell Growth in Culture and Orthotopic Xenografts by Combinational Treatment with Statin and Prodrug Farnesyltransferase Inhibitor PAMAM G4 Dendrimers.,,MCF10A,cell_lines,Experimental Usage,PUB38201517,7d3dba55-ca50-511a-be1d-8470c1224b70,USE12937665
PMID:30617350,10.1038/s41596-018-0105-7,"A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.",,murine NF2 −/− Schwann cell line,cell_lines,Experimental Usage,PUB30617350,fb87168e-a32f-5220-b2d2-5464417de4b0,USEf3b3f0a3
PMID:21111000 | PMID:38216587 | PMID:30617350 | PMID:30274821,10.1016/j.jneumeth.2010.10.021 | 10.1038/s41467-023-40408-5 | 10.1038/s41596-018-0105-7 | 10.1016/j.ebiom.2018.09.042,"A novel imaging-compatible sciatic nerve schwannoma model. | Epigenetic reprogramming shapes the cellular landscape of schwannoma. | A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.",,HEI-193,cell_lines,Experimental Usage,PUBe7e07743,30ff5a2c-69e6-5a5f-b705-6ce3ecdda69c,USE2590e7b8
PMID:35741605,10.3390/brainsci12060720,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas.,,ipNF05.5 (mixed clone),cell_lines,Experimental Usage,PUB35741605,e772bcb6-4a3b-5dab-84bd-2f8343f4d285,USE46cc18b1
PMID:35741605 | PMID:40723243,10.3390/brainsci12060720 | 10.3390/cancers17142359,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF05.5 (single clone),cell_lines,Experimental Usage,PUBad2ac02e,0fc4cc7d-3427-5f20-a1f6-b3bf0db9da74,USE065855b5
PMID:35741605 | PMID:39129390 | PMID:40862755 | PMID:36689660 | PMID:39061138 | PMID:40723243,10.3390/brainsci12060720 | 10.1002/1878-0261.13704 | 10.3390/cells14161276 | 10.1073/pnas.2208960120 | 10.3390/cancers16142498 | 10.3390/cancers17142359,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization. | A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF95.11bC,cell_lines,Experimental Usage,PUB2b259282,decace9b-a0ae-5143-9331-06a492b55a5b,USEd7793201
PMID:35741605 | PMID:33934112 | PMID:33442015 | PMID:38136356,10.3390/brainsci12060720 | 10.1038/s41419-021-03716-6 | 10.1038/s41591-020-01193-6 | 10.3390/cancers15245811,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF95.6,cell_lines,Experimental Usage,PUB8c0a7b32,c95563a3-6943-5a33-ad3c-23b1c509a267,USEd593b905
PMID:35741605 | PMID:39129390 | PMID:38136356 | PMID:40723243,10.3390/brainsci12060720 | 10.1002/1878-0261.13704 | 10.3390/cancers15245811 | 10.3390/cancers17142359,Integrated Drug Mining Reveals Actionable Strategies Inhibiting Plexiform Neurofibromas. | Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency. | The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipnNF95.11c,cell_lines,Experimental Usage,PUBad0fc128,bd2c5a12-209e-5172-bb51-6a3eccd64580,USEf306d295
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,COS-7,cell_lines,Experimental Usage,PUB40225167,6f3ef438-16e5-5ded-b91a-e0b3f8086c69,USE88d95712
PMID:21199799,10.1158/0008-5472.CAN-10-2732,Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant mice.,,Nf1-/- mouse embryo fibroblasts,cell_lines,Experimental Usage,PUB21199799,ffd2b57e-8920-5631-9047-ef384b8e5fd3,USE4e3402ae
PMID:24824755,10.1371/journal.pone.0096733,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells.,,T265-2c,cell_lines,Experimental Usage,PUB24824755,bcd30b69-1586-5ceb-abe5-4b9e19466fe4,USEb4c288c9
PMID:24824755 | PMID:20049725 | PMID:32642733 | PMID:18483311,10.1371/journal.pone.0096733 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335,BNIP3 regulates AT101 [(-)-gossypol] induced death in malignant peripheral nerve sheath tumor cells. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,90-8,cell_lines,Experimental Usage,PUB168d0863,2667d8da-de63-5e85-9ae9-59d00058b48d,USEba2110d2
PMID:24040940 | PMID:33032988,10.1186/1479-5876-11-213 | 10.1158/0008-5472.CAN-20-1365,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF96.2,cell_lines,Experimental Usage,PUB11a16d05,c1d72c0c-37a9-5f45-9603-2afdf01969a8,USE28504605
PMID:24040940,10.1186/1479-5876-11-213,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors.,,NF02.2,cell_lines,Experimental Usage,PUB24040940,dc65eb71-c590-5a4f-b241-ddd888075c31,USEac0b96f6
PMID:24040940 | PMID:33032988,10.1186/1479-5876-11-213 | 10.1158/0008-5472.CAN-20-1365,Molecular-guided therapy predictions reveal drug resistance phenotypes and treatment alternatives in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF94.3,cell_lines,Experimental Usage,PUB11a16d05,3273be64-f8a9-5cdc-a01b-c94dc69dd748,USE88fcd04a
PMID:33673681 | PMID:30531922,10.3390/cancers13050999 | 10.1038/s41591-018-0263-8,Hybrid Minigene Assay: An Efficient Tool to Characterize mRNA Splicing Profiles of | The molecular landscape of glioma in patients with Neurofibromatosis 1.,,HEK293 cells,cell_lines,Experimental Usage,PUBbb685c75,b42a808f-f6c3-5ac1-84a6-d17b6c558b6e,USE851038fd
PMID:34630515,10.3389/fgene.2021.721045,Assessment of Mosaicism and Detection of Cryptic Alleles in CRISPR/Cas9-Engineered Neurofibromatosis Type 1 and,,LLC-PK1 ATCC CL-101,cell_lines,Experimental Usage,PUB34630515,9111df47-6a9a-5c46-b54f-0661751f2960,USE07500ce2
PMID:33934112 | PMID:32457840,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,"HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,MiaPaCa-2,cell_lines,Experimental Usage,PUBd038b8e3,6cc5b753-3c9d-58f2-a150-c8734abe04eb,USE927e2c1c
PMID:33934112 | PMID:32457840,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,"HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,PANC1,cell_lines,Experimental Usage,PUBd038b8e3,26bcc0da-c9e4-572f-b1a0-03894867affa,USE77a1a2bd
PMID:33934112 | PMID:32457840,10.1038/s41419-021-03716-6 | 10.3389/fonc.2020.00687,"HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,BxPc3,cell_lines,Experimental Usage,PUBd038b8e3,e4854530-f8ed-5268-9ebc-1d61d77ab603,USE328c1abc
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,AsPC-1,cell_lines,Experimental Usage,PUB32457840,d1386129-d898-53a6-97e0-9c5b440df5e9,USE26a6d7b7
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,HPDE H6c7,cell_lines,Experimental Usage,PUB32457840,ac9fd66a-4a56-56c7-935a-f6521a4ccbe5,USE207b3c73
PMID:33273014 | PMID:28126595 | PMID:26219339 | PMID:36148553,10.1074/jbc.RA120.014960 | 10.1016/j.ebiom.2017.01.020 | 10.18632/oncotarget.4858 | 10.1093/brain/awac342,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,Ben-Men-1,cell_lines,Experimental Usage,PUBbfed82de,6715cb90-7319-5955-bd46-b1d21da7f08f,USE8d30b557
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,AC-CRISPR,cell_lines,Experimental Usage,PUB33273014,278b42a5-7b40-5c9d-bf08-b0a48350860b,USEdd7577b2
PMID:33273014,10.1074/jbc.RA120.014960,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.,,MN1-LF,cell_lines,Experimental Usage,PUB33273014,5b905bbc-dcc8-56fe-940b-3441008c4e1e,USE4e7acdc4
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,H358 cells,cell_lines,Experimental Usage,PUB38502231,012f42c4-0aaf-56e9-a583-60a3a15266fa,USEf2f11513
PMID:41022755 | PMID:32383545 | PMID:33658640 | PMID:38502231 | PMID:23328114 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:30055648 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38127282 | PMID:41001593 | PMID:32948135 | PMID:37410426 | PMID:23535903 | PMID:35511749,10.1038/s41467-025-63619-4 | 10.15252/embr.201949117 | 10.1038/s41416-021-01270-8 | 10.1172/JCI176748 | 10.18632/oncotarget.793 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1186/s13104-018-3630-0 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.1158/1078-0432.CCR-23-2548 | 10.1080/23723556.2025.2561292 | 10.1186/s12885-020-07397-w | 10.1158/1078-0432.CCR-23-0749 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-21-0947,"Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.",,S462,cell_lines,Experimental Usage,PUBece01cc9,61206236-fde5-5b73-b1d5-307009cd177c,USEaf218568
PMID:38502231 | PMID:35393510,10.1172/JCI176748 | 10.1038/s41418-022-00991-4,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD,,cis MPNST cell line,cell_lines,Experimental Usage,PUB323fc5a7,09cb80ef-92ae-5763-90f6-4c104818f6e2,USEdf3c9075
PMID:38502231,10.1172/JCI176748,STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.,,HTS-Luc MPNST cell line,cell_lines,Experimental Usage,PUB38502231,384bd83b-5359-5a91-91a2-c02ea3eb23a3,USEec716322
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,pNF9511bc,cell_lines,Experimental Usage,PUB41022755,5caa5d42-6319-50cd-aebb-631e7ec3962c,USEe28f57d8
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,ipNF03.3,cell_lines,Experimental Usage,PUB41022755,99748120-583f-5350-b9f8-cb1231cf4a6b,USE53f3bfaf
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,ipn023λ,cell_lines,Experimental Usage,PUB41022755,1cec00ad-018a-5e7e-ac4c-9ee63ce76f25,USE2373d42f
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,RHT92,cell_lines,Experimental Usage,PUB41022755,16a60b64-483c-518a-abae-07c189adef81,USEcca70cd9
PMID:41022755 | PMID:38714355,10.1038/s41467-025-63619-4 | 10.1158/1535-7163.MCT-23-0510,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,LN229,cell_lines,Experimental Usage,PUB058134e4,c865f818-8228-57eb-84d6-b7a24593eab1,USEae989ec4
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,2V6.11,cell_lines,Experimental Usage,PUB41022755,a4765cbe-ba30-544b-b731-3818d93f6b5f,USEeb534f55
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,FiPS,cell_lines,Experimental Usage,PUB41022755,4b532828-56be-5d3a-8a2f-0e288c8acfcf,USE5dac34d6
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,"NF1−/−−/− edited FiPS Ctrl1-SV4F-7, D12",cell_lines,Experimental Usage,PUB41022755,e2b415f7-c74a-5407-92da-98802525b0d2,USEc41e640f
PMID:41022755,10.1038/s41467-025-63619-4,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors.,,3PNF_SiPSsv_MM_11,cell_lines,Experimental Usage,PUB41022755,3b3f7ea5-3fb3-5674-9f21-01157693cfc0,USEa5f0cfc5
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M724,cell_lines,Experimental Usage,PUB39269317,c5e9a426-fca1-5185-a52f-ddccbacfdd9b,USE89ad1748
PMID:39269317 | PMID:23175151 | PMID:29438698 | PMID:40025578 | PMID:36322658 | PMID:35511749 | PMID:32642733 | PMID:38216572,10.1158/1078-0432.CCR-24-1750 | 10.1038/bjc.2012.518 | 10.1016/j.ccell.2018.01.005 | 10.1186/s40478-025-01965-6 | 10.1126/sciadv.abo5442 | 10.1158/1535-7163.MCT-21-0947 | 10.1093/noajnl/vdz061 | 10.1038/s41467-024-44755-9,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | MicroRNA profiling of peripheral nerve sheath tumours identifies miR-29c as a tumour suppressor gene involved in tumour progression. | Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF96.2,cell_lines,Experimental Usage,PUBb5d6cacb,14909473-2fb4-5ed1-b829-ff132be20653,USE9753d0c6
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M1,cell_lines,Experimental Usage,PUB2bd6c16e,58572cd5-257d-5a91-bce4-c2b350c55e81,USE1330a1cd
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M3,cell_lines,Experimental Usage,PUB2bd6c16e,0ba2fe44-41b5-5a53-a55e-9b75fe5f1d68,USEc019d873
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M4,cell_lines,Experimental Usage,PUB2bd6c16e,05ae7018-8e02-56bf-9b5e-d339b1e441a0,USE18f9c194
PMID:39269317,10.1158/1078-0432.CCR-24-1750,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor.,,M5,cell_lines,Experimental Usage,PUB39269317,cd2834e1-9e2b-5a0b-9a96-6836b5a86c8d,USE81ca75b2
PMID:39269317 | PMID:35789380,10.1158/1078-0432.CCR-24-1750 | 10.1158/2159-8290.CD-21-1671,MEK Inhibitors Lead to PDGFR Pathway Upregulation and Sensitize Tumors to RAF Dimer Inhibitors in NF1-Deficient Malignant Peripheral Nerve Sheath Tumor. | PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry.,,M6,cell_lines,Experimental Usage,PUB2bd6c16e,d81d9712-f258-51b8-8278-78cc50900055,USE1588d361
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,Drosophila Schneider (S2R+) cells,cell_lines,Experimental Usage,PUB39129390,8b24ba11-5bb2-5389-843f-6aec45ed87f5,USE20b1e11a
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,dNF1‐KO,cell_lines,Development,PUB39129390,ecc9f50b-8516-53ee-af1b-d0c996ab387f,USEa37cc84c
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,hTERT ipn02.3 2λ CRL‐3392,cell_lines,Experimental Usage,PUB39129390,0d3202e9-a216-508d-bbd3-eff818fc855b,USE235c3484
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,"ipnNF09.4 (hTERT NF1 ipnNF09.4, RRID: CVCL_UI73)",cell_lines,Experimental Usage,PUB39129390,db404bea-0054-592e-8ee9-2d9a343749eb,USEf920c01b
PMID:39129390 | PMID:40862755 | PMID:39061138 | PMID:33658640,10.1002/1878-0261.13704 | 10.3390/cells14161276 | 10.3390/cancers16142498 | 10.1038/s41416-021-01270-8,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors. | Fibroblasts Attenuate Anti-Tumor Drug Efficacy in Tumor Cells via Paracrine Interactions with Tumor Cells in 3D Plexiform Neurofibroma Cultures. | A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,"ipNF05.5 (hTERT NF1 ipNF05.5, RRID: CVCL_UI71)",cell_lines,Experimental Usage,PUB6189f9ee,96120edc-55b3-55fb-a2e0-dd892ef8b39f,USEa1e23e57
PMID:30531922,10.1038/s41591-018-0263-8,The molecular landscape of glioma in patients with Neurofibromatosis 1.,,U2OS,cell_lines,Experimental Usage,PUB30531922,13cfbf4b-7b85-5529-81fd-0799e3d00ab7,USE9526e844
PMID:28126595,10.1016/j.ebiom.2017.01.020,Global Proteome and Phospho-proteome Analysis of Merlin-deficient Meningioma and Schwannoma Identifies PDLIM2 as a Novel Therapeutic Target.,,Human meningeal cells (HMC),cell_lines,Experimental Usage,PUB28126595,19940322-7115-5e2f-94be-ecc5c28ab7b1,USE569c32ef
PMID:25329635,10.1371/journal.pgen.1004575,Genetic modifiers of neurofibromatosis type 1-associated café-au-lait macule count identified using multi-platform analysis.,,lymphoblastoid cell lines,cell_lines,Experimental Usage,PUB25329635,6e020ba9-4b89-51e0-9869-af3bb72e39da,USE3012b2fe
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,OLN93 mouse oligodendrocyte cell line,cell_lines,Experimental Usage,PUB29715273,aaed50c9-2844-5c59-bfc5-5c78ade18117,USEe55cf007
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,SC4-immortalized Nf2-/- primary Schwann cells,cell_lines,Experimental Usage,PUB29715273,3a050b9b-f50a-50e0-82be-af5580a2bcc1,USE4cc49875
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,RT4-D6PT2 schwannoma cell line,cell_lines,Experimental Usage,PUB29715273,df57cf04-e722-55e4-9965-40dee2f876d6,USE8ab97592
PMID:29715273,10.1371/journal.pone.0196726,Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation.,,TC620 human oligodendroglioma cell line,cell_lines,Experimental Usage,PUB29715273,520833a7-34e9-5a8b-aa08-c19e79dc0612,USE04b61aa3
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,Normal human Schwann cells (NHSC),cell_lines,Experimental Usage,PUB24509877,6793aaa0-c35a-5164-83b3-10692471e87a,USEe956f922
PMID:24509877 | PMID:18413802,10.1038/onc.2013.506 | 10.1158/1535-7163.MCT-07-0518,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,MPNST cell lines,cell_lines,Experimental Usage,PUB0329016d,5512de2b-3b60-5754-9efc-425090e750d2,USE764caaf5
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MPNST 88-14 cells,cell_lines,Experimental Usage,PUB24509877,0bb4db3d-95b6-5372-808a-c6704a2625bd,USE17f07bde
PMID:24509877,10.1038/onc.2013.506,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1.,,MPNST S462-TY cells,cell_lines,Experimental Usage,PUB24509877,73a99a79-c7e0-561a-b064-359aed15bc81,USEe282f21f
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,2884 cell line,cell_lines,Experimental Usage,PUB23328114,30a3a0f4-30d6-5d2c-a8cb-3f231d2fe2a3,USEcfab1094
PMID:23328114,10.18632/oncotarget.793,Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.,,2885 cell line,cell_lines,Experimental Usage,PUB23328114,3047a0ba-ac89-58cf-800e-4e7c1680e207,USE8aa8f120
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,hTERT NF1 ipn02.3 2λ,cell_lines,Experimental Usage,PUB36322658,9f3e8e84-4dae-5b7e-a500-10d297c4a08e,USE139dc597
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,ipn95.11bC,cell_lines,Experimental Usage,PUB36322658,3a974d02-5dd6-52a3-b71c-918c878d314a,USEc6d3f939
PMID:36322658,10.1126/sciadv.abo5442,Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy.,,MPNST642,cell_lines,Experimental Usage,PUB36322658,64ee8b55-8367-5ff0-acb6-49e2897955e6,USEcbc852ac
PMID:36322658 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:30055648 | PMID:41001593 | PMID:38203448 | PMID:32948135 | PMID:23535903,10.1126/sciadv.abo5442 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1186/s13104-018-3630-0 | 10.1080/23723556.2025.2561292 | 10.3390/ijms25010277 | 10.1186/s12885-020-07397-w | 10.1158/2159-8290.CD-13-0081,"Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Testing ATRA and MEK inhibitor PD0325901 effectiveness in a nude mouse model for human MPNST xenografts. | Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance.",,T265,cell_lines,Experimental Usage,PUB556fe557,33995551-b2f8-566f-bbba-cb638a12ba6b,USE10612592
PMID:36322658 | PMID:37164978 | PMID:24681606 | PMID:23685747 | PMID:20049725 | PMID:32642733 | PMID:18483311 | PMID:38203448 | PMID:37410426 | PMID:23535903 | PMID:35511749 | PMID:33032988,10.1126/sciadv.abo5442 | 10.1038/s41467-023-38432-6 | 10.18632/oncotarget.1609 | 10.1038/ng.2641 | 10.1002/emmm.200900027 | 10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-07-2335 | 10.3390/ijms25010277 | 10.1158/1078-0432.CCR-23-0749 | 10.1158/2159-8290.CD-13-0081 | 10.1158/1535-7163.MCT-21-0947 | 10.1158/0008-5472.CAN-20-1365,"Single-cell multiomics identifies clinically relevant mesenchymal stem-like cells and key regulators for MPNST malignancy. | Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity. | Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. | FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells. | CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression. | Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenance. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.",,STS26T,cell_lines,Experimental Usage,PUB3337a5d4,857f7dbe-27ac-5f60-80de-aa12f7080a95,USE4acb3c62
PMID:39890807,10.1038/s41598-024-84493-y,Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism.,,ipn97.4 immortalized human Schwann cells,cell_lines,Experimental Usage,PUB39890807,1a438aef-29b2-56c9-bf41-08b8b51329fa,USE21b47247
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,Schwann cells,cell_lines,Experimental Usage,PUB37520682,45e82643-6f9d-5f5a-842e-b288e3703d7f,USEef93c1c4
PMID:34040258,10.1038/s41586-021-03580-6,NF1 mutation drives neuronal activity-dependent initiation of optic glioma.,,optic glioma cells,cell_lines,Experimental Usage,PUB34040258,6d101a5b-0f0e-5148-91f6-8e033fd471ce,USE6f371e63
PMID:37164978,10.1038/s41467-023-38432-6,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities.,,HSC1λ,cell_lines,Experimental Usage,PUB37164978,16b9df1e-b09c-5691-af15-0464246c2942,USE1c445731
PMID:37164978 | PMID:38136356,10.1038/s41467-023-38432-6 | 10.3390/cancers15245811,Multiplatform molecular profiling uncovers two subgroups of malignant peripheral nerve sheath tumors with distinct therapeutic vulnerabilities. | Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF06.2A,cell_lines,Experimental Usage,PUBc1ed5c82,57fd30a0-521e-59f8-80f1-ddfe31e9c772,USEd3a3f6c3
PMID:40590220 | PMID:36420221 | PMID:32383545,10.1172/JCI188932 | 10.1016/j.omtn.2022.10.026 | 10.15252/embr.201949117,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice. | Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype | Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca,,HeLa cells,cell_lines,Experimental Usage,PUB3f27522a,db3db0ae-5a93-506d-bef3-17718bbb4158,USEd9981329
PMID:32383545 | PMID:37446790,10.15252/embr.201949117 | 10.3390/molecules28135128,Hexokinase 2 displacement from mitochondria-associated membranes prompts Ca | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway.,,C2C12 cells,cell_lines,Experimental Usage,PUB4be6d563,ae2135e1-4d74-5f96-b026-ec9873d49eb2,USE1e0d5b59
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,NF1-1 hiPSC line,cell_lines,Experimental Usage,PUB38481529,1760a885-37db-59e7-a79d-b0749772a6d8,USE68abe399
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,NF1-2 hiPSC line,cell_lines,Experimental Usage,PUB38481529,f06517b7-580b-5060-8de6-1918e745f09d,USE32eaea33
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,WT-1 hiPSC line,cell_lines,Experimental Usage,PUB38481529,00a4afb5-a6d7-5227-9041-942a7781cddc,USE9d1a4c8f
PMID:38481529,10.3389/fcell.2024.1359561,Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1.,,WT-2 hiPSC line,cell_lines,Experimental Usage,PUB38481529,6ea53b58-c0ec-519b-8b9d-eff75a906795,USEae0b4b7b
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,LUVA cells,cell_lines,Experimental Usage,PUB40590220,b55bee8c-2e29-594b-8678-d3325c18143b,USE8538e7f5
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Human Schwann Cells (HSC, ScienCell Research Laboratories #1700)",cell_lines,Experimental Usage,PUB38216587,0db1eb5c-a4d2-5c75-bee1-c3f9e4c42cef,USE911fa3f2
PMID:38216587,10.1038/s41467-023-40408-5,Epigenetic reprogramming shapes the cellular landscape of schwannoma.,,"Mouse Schwann Cells (MSC, ScienCell Research Laboratories #M1700-57)",cell_lines,Experimental Usage,PUB38216587,318750a4-ea8b-515a-bd7a-76c3784c36c3,USE7b997fb1
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,NF37,cell_lines,Experimental Usage,PUB29941005,9fad9960-2016-5753-9866-0c939222bcd5,USE7b71047b
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,NF87,cell_lines,Experimental Usage,PUB29941005,9e1f94af-229c-5c37-aabe-d5db89723c2e,USEac4cb954
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT10,cell_lines,Experimental Usage,PUB29941005,5b5c5912-0cf3-5631-8ba2-1c2e4a45c1ea,USEc2ecf0c2
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT11,cell_lines,Experimental Usage,PUB29941005,d408830f-dc82-574d-b204-559ba820d989,USE2bcfee78
PMID:29941005,10.1186/s13023-018-0843-1,Increased extracellular matrix deposition during chondrogenic differentiation of dental pulp stem cells from individuals with neurofibromatosis type 1: an in vitro 2D and 3D study.,,CT12,cell_lines,Experimental Usage,PUB29941005,9af1d3b0-91b2-5461-af1d-209ef38629f4,USE2e862478
PMID:29438698 | PMID:38216572,10.1016/j.ccell.2018.01.005 | 10.1038/s41467-024-44755-9,Programming of Schwann Cells by Lats1/2-TAZ/YAP Signaling Drives Malignant Peripheral Nerve Sheath Tumorigenesis. | Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF02.2,cell_lines,Experimental Usage,PUB61b2d569,7d07e1d2-fe8d-57ac-9d87-7f4040b54729,USE25d02b32
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,TM-31,cell_lines,Experimental Usage,PUB36730269,274be0a0-e9df-5860-8892-72cb9887d099,USE646ae8f4
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,LN319,cell_lines,Experimental Usage,PUB36730269,299a9e12-545a-533a-9848-39f085721fd1,USE23f66ed2
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,17,cell_lines,Experimental Usage,PUB36730269,35158f01-4e4f-5a4c-93cc-058b269bf7ce,USE44cab8cc
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,5653,cell_lines,Experimental Usage,PUB36730269,9b0a4c5f-a9d1-5418-96cc-961164037e28,USEefb0eeb6
PMID:36730269,10.1371/journal.pone.0277305,Identification of therapeutic sensitivities in a spheroid drug combination screen of Neurofibromatosis Type I associated High Grade Gliomas.,,5746,cell_lines,Experimental Usage,PUB36730269,7ab1a9a6-fbdd-5c18-8942-e94bfdf6ef28,USE31ccf646
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,"Human Schwann cells (HSC; ScienCell, Carlsbad, CA)",cell_lines,Experimental Usage,PUB20195187,02846028-6445-5e63-bba0-8ac632254763,USEb734a327
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,LS141,cell_lines,Experimental Usage,PUB18413802,66c70328-85a9-5e0d-8042-37528bd5f087,USE16100690
PMID:18413802,10.1158/1535-7163.MCT-07-0518,Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.,,DDLS,cell_lines,Experimental Usage,PUB18413802,064964d4-f8ec-5add-a40c-3abad4aa78d1,USEa5283281
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,Human Schwann cells (HSCs),cell_lines,Experimental Usage,PUB30274821,12895209-2ffe-54b9-99eb-02d7c91ae8e6,USE4e5d18e2
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,RT4-D6P2T schwannoma cells,cell_lines,Experimental Usage,PUB30274821,7f248fad-3eba-5240-9e11-aae2a861d9c8,USE4ad7d94d
PMID:20554030,10.1016/j.jneuroim.2010.05.002,CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice.,,LN428 human glioblastoma multiforme (GBM) cell line,cell_lines,Experimental Usage,PUB20554030,7381a36e-0cd3-5b7d-9b6e-553506c81e7b,USE333c55cd
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,BL21(DE3) Star,cell_lines,Experimental Usage,PUB28831766,d1c9b566-0c52-5b23-9fce-761eed670430,USEe849debd
PMID:36689660,10.1073/pnas.2208960120,Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,NF1-null 293T cells,cell_lines,Experimental Usage,PUB36689660,bc896f98-e6ed-578c-b02e-d5c68001d49d,USE6a479bca
PMID:28392281 | PMID:34065204,10.1016/j.expneurol.2017.04.001 | 10.3390/ijms22105367,Human stem cell modeling in neurofibromatosis type 1 (NF1). | RABL6A Regulates Schwann Cell Senescence in an RB1-Dependent Manner.,,mouse embryonic fibroblasts (MEFs),cell_lines,Experimental Usage,PUB46ecf57f,441c9238-67d2-506c-a607-419d96a3b689,USEd4f59435
PMID:38000020 | PMID:38127282 | PMID:33032988,10.1126/sciadv.adg8876 | 10.1158/1078-0432.CCR-23-2548 | 10.1158/0008-5472.CAN-20-1365,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2-002,cell_lines,Experimental Usage,PUBb9258046,0e1ef12a-918c-5632-b5ca-6a8d3bff1105,USEb48f393b
PMID:38000020 | PMID:33032988,10.1126/sciadv.adg8876 | 10.1158/0008-5472.CAN-20-1365,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2-031,cell_lines,Experimental Usage,PUBa15b955f,abf9906f-e801-5772-98d1-23f1ab670210,USEd0521645
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-079c,cell_lines,Experimental Usage,PUB38000020,4a0443c7-a980-5c3b-9c83-9f42d09127f6,USE882ad06d
PMID:38000020 | PMID:38127282,10.1126/sciadv.adg8876 | 10.1158/1078-0432.CCR-23-2548,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,JH-2-103,cell_lines,Experimental Usage,PUBcb7cca4f,0d57eb6f-37e3-5c9c-8096-c8703db37579,USE8e151dab
PMID:23685747 | PMID:41036607,10.1038/ng.2641 | 10.1158/1535-7163.MCT-24-1053,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,iHSCs,cell_lines,Experimental Usage,PUB2c295693,eb060f63-0452-520f-a98b-5e20770c00a3,USE1e0226ed
PMID:23685747 | PMID:40025578,10.1038/ng.2641 | 10.1186/s40478-025-01965-6,Forward genetic screen for malignant peripheral nerve sheath tumor formation identifies new genes and pathways driving tumorigenesis. | Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,K562,cell_lines,Experimental Usage,PUB62b99413,eacac9ed-5266-56f0-9d8b-38b1b0c9ba6a,USEcf430d87
PMID:41564118 | PMID:38907342,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF97.2a,cell_lines,Development,PUBe5a5ea03,c5eab181-010c-53e7-b11e-29b4c9ae3167,USE4542402e
PMID:41564118 | PMID:38907342,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF97.2b,cell_lines,Development,PUBe5a5ea03,05069634-3b1d-5ad3-9c24-0d974e469302,USE945c1070
PMID:41564118 | PMID:38907342,10.1371/journal.pone.0340183 | 10.1186/s40478-024-01821-z,"Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas. | snRNA-seq of human cutaneous neurofibromas before and after selumetinib treatment implicates role of altered Schwann cell states, inter-cellular signaling, and extracellular matrix in treatment response.",,icNF98.4d,cell_lines,Development,PUBe5a5ea03,6e93c382-29ba-548e-b7cc-c863cd81b98d,USE09c5fb64
PMID:40025578 | PMID:25026211 | PMID:26219339,10.1186/s40478-025-01965-6 | 10.1016/j.ccr.2014.05.001 | 10.18632/oncotarget.4858,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment. | Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,293T cells,cell_lines,Experimental Usage,PUBd9b452bd,e8626696-31a8-5ce5-85ba-eafdf85a9081,USEde46f218
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,HFFs,cell_lines,Experimental Usage,PUB40025578,c4cd60d8-b8d3-5e23-8169-e9f9aa19c889,USE5a51b9a4
PMID:40025578,10.1186/s40478-025-01965-6,Development of CAR-T cell therapy for NF1/SWN-related nerve sheath tumor treatment.,,NCI-H266,cell_lines,Experimental Usage,PUB40025578,6e520e64-5b89-505e-b1c6-b07c0d2d47aa,USE01a6d9f6
PMID:34011935,10.1038/s41419-021-03802-9,Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine.,,Neurofibromatosis 1 fibroblasts,cell_lines,Experimental Usage,PUB34011935,d801b6e8-d449-515a-93ad-5d8e0133ae7d,USE6992c8e1
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-SP-01,cell_lines,Experimental Usage,PUB35511749,40210d2d-9336-51b4-b9db-f804f59a70bd,USEb3b752a7
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-08,cell_lines,Experimental Usage,PUB35511749,8d54897a-5c5d-523b-b534-4b2e8aa80286,USE4257d43b
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-9,cell_lines,Experimental Usage,PUB35511749,17bbbdea-39a6-5035-9fab-edd9c988df07,USE3218cb28
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,HS-PSS,cell_lines,Experimental Usage,PUB35511749,8381baf7-b584-5734-864d-6990e37ca550,USEcbc6e056
PMID:32642733 | PMID:35511749,10.1093/noajnl/vdz061 | 10.1158/1535-7163.MCT-21-0947,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors. | A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,HS-Sch-2,cell_lines,Experimental Usage,PUBbaf4f291,435d01d8-e503-5fba-a288-26f4c5a7c143,USEdf1ac38e
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,Human Foreskin Fibroblast (HFF),cell_lines,Experimental Usage,PUB35511749,ecdf2706-b174-572d-9103-02029186533d,USE41e236ae
PMID:39061138,10.3390/cancers16142498,A Fibroblast-Derived Secretome Stimulates the Growth and Invasiveness of 3D Plexiform Neurofibroma Spheroids.,,ipNF95.11b C-RFP,cell_lines,Experimental Usage,PUB39061138,f81032de-94dd-5492-98a8-571cd6727fa4,USEa2f16f1d
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,AC007-hTERT,cell_lines,Experimental Usage,PUB26219339,23d9a69b-945e-538c-8e8b-52b9b79983d0,USE31cc8ad8
PMID:26219339,10.18632/oncotarget.4858,A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.,,AC028,cell_lines,Experimental Usage,PUB26219339,38bed69c-8c07-53f1-aa00-08c26becbb26,USE2927d574
PMID:28166733,10.1186/s12864-017-3519-7,A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.,,U87-MG,cell_lines,Experimental Usage,PUB28166733,9bffcee2-110a-5f30-a83f-5349091ab434,USE90d9923f
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,Meso-33,cell_lines,Experimental Usage,PUB25026211,5d1eb25f-d9d0-56d8-9d0d-c231ac92a03e,USE1414fbea
PMID:25026211,10.1016/j.ccr.2014.05.001,Merlin/NF2 loss-driven tumorigenesis linked to CRL4(DCAF1)-mediated inhibition of the hippo pathway kinases Lats1 and 2 in the nucleus.,,FC-1801,cell_lines,Experimental Usage,PUB25026211,89d138e5-0f23-56da-90b7-17213e525529,USE54c80388
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,NIH-3T3,cell_lines,Experimental Usage,PUB21072183,901d010a-831b-5221-a14a-3fd465e9c1de,USEe191390a
PMID:21072183,10.1371/journal.pone.0013791,p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.,,φNX packaging cell line,cell_lines,Experimental Usage,PUB21072183,e569d9f6-0608-5741-ba68-3259feacc272,USE1730448d
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,H1838,cell_lines,Experimental Usage,PUB33032988,d96837ab-ca54-5f40-afd9-0b7ede0f172f,USE47348435
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,WM3918,cell_lines,Experimental Usage,PUB33032988,2286ee1a-9330-5bf4-ab3c-c46362e5d070,USE95cf342e
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,M308,cell_lines,Experimental Usage,PUB33032988,4f4adb1b-8529-58fe-aa4c-3a99cf63acf0,USE53abb4be
PMID:18367665 | PMID:33658640 | PMID:33032988,10.1124/jpet.107.135830 | 10.1038/s41416-021-01270-8 | 10.1158/0008-5472.CAN-20-1365,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin. | Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF90-8,cell_lines,Experimental Usage,PUBf8e8a007,2859c032-ab81-5e1e-b05c-9043e10e6982,USE23a7af8a
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF10.1,cell_lines,Experimental Usage,PUB33032988,f6f389ee-1913-5b51-9e9d-60718392f57d,USE04c1b992
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,NF11.1,cell_lines,Experimental Usage,PUB33032988,6cd8aa27-1517-5cb7-9ccc-c3776d7be0c1,USEe1b86666
PMID:21216928,10.1158/1535-7163.MCT-10-0654,Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.,,K4622 grade II glioma cell line,cell_lines,Experimental Usage,PUB21216928,6b8fd2c3-41d4-52bf-9a7d-1969f1422589,USE4cd892e2
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,HSR-GBM1,cell_lines,Experimental Usage,PUB38714355,762b37cf-abef-5668-ab53-d37ef4a0bcda,USE95898ca0
PMID:39472976 | PMID:38714355,10.1186/s40478-024-01875-z | 10.1158/1535-7163.MCT-23-0510,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes. | MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHH-520 cell line,cell_lines,Experimental Usage,PUBcf268d95,49c24d32-1f3e-5e44-8337-d5837d36adae,USE71d59fc2
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHU-0879,cell_lines,Experimental Usage,PUB38714355,0d04bfc5-f3eb-58ae-aba5-96690c0cfbfb,USEbdec9c44
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHU-1016B,cell_lines,Experimental Usage,PUB38714355,02151179-f287-5580-abd5-2ac2cbc4c692,USE26779c07
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,JHH-136,cell_lines,Experimental Usage,PUB38714355,82df4dd9-a6dc-5203-920c-ea805bc2b4cf,USE300ed0ca
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,B76,cell_lines,Experimental Usage,PUB38714355,a30cb5fb-b05b-5f83-bb30-996e8fbfc76c,USE0a1bd05a
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NGT-41,cell_lines,Experimental Usage,PUB38714355,e9cebee0-b3a6-597f-8b44-15271a6f53a4,USEa0ec475e
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,NMCG-1,cell_lines,Experimental Usage,PUB38714355,96057038-9982-57a5-b50d-b4f8dd789948,USE4c853b69
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,DBTRG,cell_lines,Experimental Usage,PUB38714355,99a0ff7c-1a5f-5eb0-87da-fa7e21f9ceeb,USE1006d2f9
PMID:38714355,10.1158/1535-7163.MCT-23-0510,MEK Inhibition Enhances the Antitumor Effect of Radiotherapy in NF1-Deficient Glioblastoma.,,T98G,cell_lines,Experimental Usage,PUB38714355,3549582f-ff39-5bfd-9c26-00e57d7805ae,USE025ebefd
PMID:32419643 | PMID:33934112 | PMID:25043298,10.1177/1533033820919759 | 10.1038/s41419-021-03716-6 | 10.1038/onc.2014.185,Long Noncoding RNA WT1-AS Inhibit Cell Malignancy via miR-494-3p in Glioma. | HIF1α-dependent induction of the mitochondrial chaperone TRAP1 regulates bioenergetic adaptations to hypoxia. | Oncogenic role of Merlin/NF2 in glioblastoma.,,U251,cell_lines,Experimental Usage,PUB396b63ee,07eab8f2-f28c-5ea9-b326-a0c94aa93543,USE034fc5bc
PMID:25340526,10.1371/journal.pone.0107760,Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.,,PNF-derived Schwann cells,cell_lines,Experimental Usage,PUB25340526,9c2a04f2-e089-5e02-9ca9-9469e88a1762,USE7366790e
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,GBM1 cell line,cell_lines,Experimental Usage,PUB39472976,f7e2bb13-b9f5-5efc-a11e-4f2d3e0de0bb,USE31882738
PMID:39472976,10.1186/s40478-024-01875-z,NF1 expression profiling in IDH-wildtype glioblastoma: genomic associations and survival outcomes.,,JHH-0879 cell line,cell_lines,Experimental Usage,PUB39472976,4ee95ac2-12db-5825-b4fc-fb2d8d0726ef,USEc07c044b
PMID:20049725 | PMID:18483311,10.1002/emmm.200900027 | 10.1158/1535-7163.MCT-07-2335,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,S520,cell_lines,Experimental Usage,PUBbd46e5f9,622ddce9-3f48-5a21-8b4a-bbc4ea4219c2,USE70f00be1
PMID:20049725,10.1002/emmm.200900027,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene.,,88-3,cell_lines,Experimental Usage,PUB20049725,be58e700-bdd6-5072-9b52-fb4f88c3eb7d,USE9bca7ecf
PMID:20049725 | PMID:18483311,10.1002/emmm.200900027 | 10.1158/1535-7163.MCT-07-2335,Integrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival gene. | Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,YST1,cell_lines,Experimental Usage,PUBbd46e5f9,73fcc875-6ee3-59bb-8aa3-9fe75b50d858,USE13fdef44
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF98.4c,cell_lines,Development,PUB41564118,69545a99-0d1d-50f0-87d9-9d4b28f1ab5c,USE388aeb38
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF00.10a,cell_lines,Development,PUB41564118,df25f9d1-b685-5fff-bc04-de2389b51c64,USEae91ad03
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,icNF04.9a,cell_lines,Development,PUB41564118,bb399a47-3006-5d54-8754-c067e5a785a0,USE2852c773
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i28cNF,cell_lines,Development,PUB41564118,4bc93c3e-3ee1-52da-b265-85b9b1858403,USE6ec36049
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i18cNF,cell_lines,Development,PUB41564118,b4d373d2-fec6-599c-a8e0-85102e5ab336,USE85979a13
PMID:41564118,10.1371/journal.pone.0340183,Immortalization and characterization of Schwann cell lines derived from NF1-associated cutaneous neurofibromas.,,i21cNF,cell_lines,Development,PUB41564118,47a890ce-e8e1-58e9-abd1-396f30119ee4,USE7574f924
PMID:32642733,10.1093/noajnl/vdz061,KIF11 and KIF15 mitotic kinesins are potential therapeutic vulnerabilities for malignant peripheral nerve sheath tumors.,,CCD-1112Sk,cell_lines,Experimental Usage,PUB32642733,b0020082-8199-5bf0-93fd-7d29f2da1365,USE1993ad81
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Rosetta2(DE3) competent cells,cell_lines,Experimental Usage,PUB24882693,99356176-3cc2-5af4-a888-42ba353f379c,USE43bbe635
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,ST88-3,cell_lines,Experimental Usage,PUB18483311,d101dfd6-6d34-512a-8c60-671a059abad3,USE3fb648e9
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,T265p21,cell_lines,Experimental Usage,PUB18483311,d6faa9df-da18-5590-9ecc-1f9eee8532f9,USE5f17dcd4
PMID:18483311,10.1158/1535-7163.MCT-07-2335,Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors.,,DS-red STS26T cell line,cell_lines,Experimental Usage,PUB18483311,be4fc082-9500-5bc9-9d17-9aa1444b22a1,USEd939e90a
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,hTERT ipNF05.5,cell_lines,Experimental Usage,PUB37140985,bc5b871f-4310-5cbd-b4d7-6bc40e5ae7dd,USE7bcbf489
PMID:37140985 | PMID:38127282,10.1172/JCI168227 | 10.1158/1078-0432.CCR-23-2548,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. | Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,hTERT ipn02.3 2λ,cell_lines,Experimental Usage,PUB5d46f60e,cfcf7036-c25c-587f-8308-4d95cf988d38,USE74db0992
PMID:37140985,10.1172/JCI168227,Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor.,,E13.5 DRG neurosphere cells,cell_lines,Experimental Usage,PUB37140985,8f78ce72-6d9c-590f-9091-ee42d875b5c5,USEd916fe40
PMID:20551058,10.1158/0008-5472.CAN-09-3769,Cyclic AMP suppression is sufficient to induce gliomagenesis in a mouse model of neurofibromatosis-1.,,Daoy,cell_lines,Experimental Usage,PUB20551058,7f63a873-2316-525c-8db0-67a071e3fa44,USEf0b95072
PMID:38175707,10.1172/jci.insight.168826,Unbalancing cAMP and Ras/MAPK pathways as a therapeutic strategy for cutaneous neurofibromas.,,NF1-/- iPSC-derived neural crest cells,cell_lines,Experimental Usage,PUB38175707,f31b01d0-5fd9-59a8-b044-3665fe3e9236,USEdd0eb8d3
PMID:38127282,10.1158/1078-0432.CCR-23-2548,Spatial Gene-Expression Profiling Unveils Immuno-oncogenic Programs of NF1-Associated Peripheral Nerve Sheath Tumor Progression.,,hTERT NF1 ipNF95.6 cell line,cell_lines,Experimental Usage,PUB38127282,9cac64e8-0ab3-50f0-a626-862876b9d5f8,USE6380c3f3
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF05.5-MX,cell_lines,Experimental Usage,PUB38136356,23b8d261-4be1-5dec-a174-3bc7647bc94f,USE2aaa2454
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF95.11b C/T,cell_lines,Experimental Usage,PUB38136356,abd7894b-6f36-57e2-8cd7-c6ef1e190c68,USEd30b26e8
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF02.3 2λ,cell_lines,Experimental Usage,PUB38136356,e4c7659a-3505-5413-aca5-395f2a0c10f8,USEf172b7fb
PMID:38136356,10.3390/cancers15245811,Drug Responses in Plexiform Neurofibroma Type I (PNF1) Cell Lines Using High-Throughput Data and Combined Effectiveness and Potency.,,ipNF02.8,cell_lines,Experimental Usage,PUB38136356,3565927d-e858-5eac-aeea-3b0bfad42bdf,USE56945ca5
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,NF95.11b,cell_lines,Experimental Usage,PUB38216572,4759e8ba-b29a-58eb-bad8-160f243e4f6e,USEd2c25c40
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,NF95.6,cell_lines,Experimental Usage,PUB38216572,6c3cc53f-b3e5-58dc-bbe2-f0a8d11e9a76,USE122962ab
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,SNF94.3,cell_lines,Experimental Usage,PUB38216572,cda1c13a-47d6-5e8a-933f-805a61108d62,USE012f6371
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,JW18.2,cell_lines,Experimental Usage,PUB38216572,cf536d94-52ae-5b02-b0af-27ea0bcd85aa,USE144c34f3
PMID:38216572,10.1038/s41467-024-44755-9,Functional interactions between neurofibromatosis tumor suppressors underlie Schwann cell tumor de-differentiation and treatment resistance.,,JW23.3,cell_lines,Experimental Usage,PUB38216572,bdaa0134-6ccc-58a1-96fe-06048cca5f31,USE3c21bd47
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,KT21-MG1,cell_lines,Experimental Usage,PUB36148553,e0c247ed-04f8-5270-bb80-c82f5b38bcaf,USE43f3f9ce
PMID:36148553,10.1093/brain/awac342,Inhibition of YAP/TAZ-driven TEAD activity prevents growth of NF2-null schwannoma and meningioma.,,293FT,cell_lines,Experimental Usage,PUB36148553,460c872a-9d2f-5138-96ec-d90b4c3c07d5,USE1ed2fe58
PMID:36420221,10.1016/j.omtn.2022.10.026,Antisense oligonucleotides targeting exon 11 are able to partially rescue the NF2-related schwannomatosis phenotype,,NF2 primary fibroblasts,cell_lines,Experimental Usage,PUB36420221,3b885fc6-2b81-5135-b19d-41858172ab16,USE2fba8a68
PMID:32438526,10.1002/lary.28671,Effects of Neurod1 Expression on Mouse and Human Schwannoma Cells.,,Primary human vestibular schwannoma (VS) cell cultures,cell_lines,Experimental Usage,PUB32438526,fa2d697c-87d5-5ca6-8521-55dfc7fcb50f,USEb49a1d20
PMID:18367665,10.1124/jpet.107.135830,Induction of apoptosis in neurofibromatosis type 1 malignant peripheral nerve sheath tumor cell lines by a combination of novel farnesyl transferase inhibitors and lovastatin.,,Primary normal rat Schwann cells,cell_lines,Experimental Usage,PUB18367665,59af1a48-5ee8-5532-90c0-5083623295ab,USE27fecbe7
PMID:40723243,10.3390/cancers17142359,The Combination of HSP90 Inhibitors and Selumetinib Reinforces the Inhibitory Effects on Plexiform Neurofibromas.,,ipNF05.5 Mixed Clones,cell_lines,Experimental Usage,PUB40723243,288557ae-3aa6-5fe4-b4f2-c31f47d02d5c,USEec71b29b
PMID:25043591,10.1002/jbmr.2316,Combined MEK inhibition and BMP2 treatment promotes osteoblast differentiation and bone healing in Nf1Osx -/- mice.,,Nf1flox/flox bone marrow stromal cells,cell_lines,Experimental Usage,PUB25043591,2cfe2fe7-e0f5-5eec-8a23-6ca6e83eb7ad,USEfd3aab5b
PMID:19144871,10.3181/0809-RM-275,Identification of erythrocyte p55/MPP1 as a binding partner of NF2 tumor suppressor protein/Merlin.,,DH5α bacteria,cell_lines,Experimental Usage,PUB19144871,7480155a-57b0-57dc-922d-abf33faa35e1,USE1f5449a4
PMID:28392281,10.1016/j.expneurol.2017.04.001,Human stem cell modeling in neurofibromatosis type 1 (NF1).,,tail-tip fibroblasts (TTFs),cell_lines,Experimental Usage,PUB28392281,ac5786d9-0742-5caf-a7fc-62296288ec15,USE4f4401f3
PMID:36241865,10.1038/s12276-022-00850-9,Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Neural stem cells,cell_lines,Experimental Usage,PUB36241865,e4274a5c-5e95-5610-aeb8-5fa130b1f8c4,USE4c7c56c5
PMID:24817309,10.1371/journal.pone.0097320,Nf2/Merlin controls spinal cord neural progenitor function in a Rac1/ErbB2-dependent manner.,,Nf2-deficient spinal cord neural progenitor cells,cell_lines,Experimental Usage,PUB24817309,ef45ea0c-0c92-5916-b2bb-3e9c6f13c3ac,USEea71ab71
PMID:41001593 | PMID:32948135,10.1080/23723556.2025.2561292 | 10.1186/s12885-020-07397-w,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor. | Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,NSF1,cell_lines,Experimental Usage,PUB05aef37d,a294f2eb-af7f-5ab4-887a-5bc0b414a9bb,USE285fab03
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,BRGN,cell_lines,Experimental Usage,PUB41001593,34ebc8df-ab6a-570c-9a4d-1715a7c7f0e1,USE9e553640
PMID:41001593,10.1080/23723556.2025.2561292,Loss of Schwann cell's normal rhythmic core clock gene expression and gain of rhythmic expression of oncogenic driver genes in malignant NF1-associated peripheral nerve sheath tumor.,,primary human Schwann cells (HSC),cell_lines,Experimental Usage,PUB41001593,c60fdd8e-c993-5ad6-874b-29c519f3858c,USE1a2a80bf
PMID:38203448,10.3390/ijms25010277,FT895 Impairs Mitochondrial Function in Malignant Peripheral Nerve Sheath Tumor Cells.,,Normal human Schwann cells (HSC),cell_lines,Experimental Usage,PUB38203448,3254ce41-7862-57ab-935c-4b6f282d4738,USE6c8cdfc2
PMID:32948135,10.1186/s12885-020-07397-w,Anti-cancer agent 3-bromopyruvate reduces growth of MPNST and inhibits metabolic pathways in a representative in-vitro model.,,B8 fibroblasts,cell_lines,Experimental Usage,PUB32948135,7f3d32b3-ede5-5eb8-9a19-d166f7b27814,USE836511e8
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,95.6,cell_lines,Experimental Usage,PUB33658640,995f5d9c-d3eb-5dbf-822d-dd2a4bca5a8b,USEf1f054e4
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,ipn02.3,cell_lines,Experimental Usage,PUB33658640,f3d45911-0f4c-54fa-a862-1433f7460f1f,USE82629228
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,2020,JH-2–009,cell_lines,Experimental Usage,PUB33032988,194c9a0e-18ca-5ebb-9e5e-93a962a93163,USEc7acfdb3
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,2020,JH-2–055,cell_lines,Experimental Usage,PUB33032988,e0625198-9dc5-521c-82ef-a61e1158c796,USEb2c1099e
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,2020,JH-2–060,cell_lines,Experimental Usage,PUB33032988,d420daba-7fa5-5556-aa66-a9d02c26af82,USE05d689f5
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,2020,JH-2–074,cell_lines,Experimental Usage,PUB33032988,220fb2ec-c4d5-52d8-9fc6-8059b1ac6f56,USE1ac75629
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,2020,JH-2–077,cell_lines,Experimental Usage,PUB33032988,c1327f0c-441a-5f3c-a9e3-5ef76df56153,USEeafd84d7
PMID:38811427,10.1186/s41687-024-00732-w,Quality of life in individuals with neurofibromatosis type 1 associated cutaneous neurofibromas: validation of the Dutch cNF-Skindex.,,cNF-Skindex,clinical_assessment_tools,Experimental Usage,PUB38811427,41690aa7-93cc-5c85-8579-9367d647b0b1,USEe5aa7976
PMID:28193237,10.1186/s12955-017-0607-y,Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.,,Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire,clinical_assessment_tools,Development,PUB28193237,8d085b33-a06f-5476-957f-c1d438011c8c,USEbd1864a7
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Cirrus HD-OCT,clinical_assessment_tools,Experimental Usage,PUB38990917,57f38f1c-aef0-5b8b-a0d6-1150edeeab07,USEb3f6f962
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Teller acuity cards,clinical_assessment_tools,Experimental Usage,PUB38990917,36ba0734-10fe-5733-b761-fed8ba10b043,USE1de06c15
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Cardiff acuity cards,clinical_assessment_tools,Experimental Usage,PUB38990917,e4d24f91-9ec0-5c15-bccb-11594e0f2602,USE7ffcebc3
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Lea cards,clinical_assessment_tools,Experimental Usage,PUB38990917,71b9e485-eb19-5321-b8b5-cccda706fe04,USE43b115f7
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,KM (Konstantin Moutakis) cards,clinical_assessment_tools,Experimental Usage,PUB38990917,dd140fcf-1389-5b90-94da-8978ca70bf86,USE2e311d10
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,Humphrey Field Analyzer perimetry,clinical_assessment_tools,Experimental Usage,PUB38990917,cbb461af-25d6-591f-864c-b4808d7d6989,USE4fc5e063
PMID:38990917,10.1371/journal.pone.0305548,Optical coherence tomography of the macular ganglion cell layer in children with neurofibromatosis type 1 is a useful tool in the assessment for optic pathway gliomas.,,World Health Organization Categories of Childhood VI scale,clinical_assessment_tools,Experimental Usage,PUB38990917,814144de-175f-512e-9299-125ece9cc7e4,USE9af56eba
PMID:40737523,10.2196/71728,Clinician Perspectives of a Magnetic Resonance Imaging-Based 3D Volumetric Analysis Tool for Neurofibromatosis Type 2-Related Schwannomatosis: Qualitative Pilot Study.,,Likert scale questionnaire,clinical_assessment_tools,Experimental Usage,PUB40737523,5b689dd7-5fc9-567b-9415-ba38fc1d245c,USEf1fadf5e
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,BoN (Burden of NF1) questionnaire,clinical_assessment_tools,Development,PUB31053133,bd963f64-921c-550d-9232-3c624b167c15,USE6e0c47f0
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,Dermatology Life Quality Index (DLQI),clinical_assessment_tools,Experimental Usage,PUB31053133,d3b1dfbf-71ee-5e64-aa45-833969852d65,USE2d089f26
PMID:31053133,10.1186/s13023-019-1067-8,Burden of adult neurofibromatosis 1: development and validation of a burden assessment tool.,,SF12,clinical_assessment_tools,Experimental Usage,PUB31053133,cd5ce5c7-6228-5faf-9949-4ca03c7e99c1,USE54dafaa0
PMID:33085177 | PMID:38499890,10.1002/mgg3.1530 | 10.1186/s41687-024-00714-y,"The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas. | The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.",,PlexiQoL,clinical_assessment_tools,Development,PUBc472289e,1b6e2a2a-af7b-595c-ac77-fca8a5b13e5d,USEa7153d4e
PMID:34106871,10.1109/JBHI.2021.3087735,DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.,,DINs (Deep Interactive Networks),computational_tools,Development,PUB34106871,4a49f884-8997-5884-939d-d32a027ba173,USEc4be654d
PMID:40887659,10.1186/s40246-025-00803-z,RENOVO-NF1 accurately predicts NF1 missense variant pathogenicity.,,RENOVO-NF1,computational_tools,Development,PUB40887659,f6f44b1b-1184-59e7-83fd-bc9eade2284f,USE709185ef
PMID:35589737,10.1038/s41467-022-30466-6,Neuronal hyperexcitability drives central and peripheral nervous system tumor progression in models of neurofibromatosis-1.,,shNF1,genetic_reagents,Experimental Usage,PUB35589737,31f7668c-a012-593c-8da4-f3cd33132a7f,USE4e5f391d
PMID:38216123,10.1016/j.molmet.2024.101876,NF1 deficiency drives metabolic reprogramming in ER+ breast cancer.,,NF1 gRNA,genetic_reagents,Experimental Usage,PUB38216123,bca1003e-cc07-5aef-bafa-63c5c19414f9,USEdc7460f1
PMID:31836666 | PMID:36689660,10.1074/jbc.RA119.010934 | 10.1073/pnas.2208960120,Biochemical and structural analyses reveal that the tumor suppressor neurofibromin (NF1) forms a high-affinity dimer. | Destabilizing NF1 variants act in a dominant negative manner through neurofibromin dimerization.,,NF1 isoform 2,genetic_reagents,Experimental Usage,PUB021451f7,06cfd3ee-3729-5709-b480-369992a65417,USE25e855b1
PMID:33273014 | PMID:29715273 | PMID:30274821 | PMID:26219339 | PMID:24595234,10.1074/jbc.RA120.014960 | 10.1371/journal.pone.0196726 | 10.1016/j.ebiom.2018.09.042 | 10.18632/oncotarget.4858 | 10.1371/journal.pone.0090853,mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. | Neurofibromatosis type 2 tumor suppressor protein is expressed in oligodendrocytes and regulates cell proliferation and process formation. | Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors. | A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. | In vivo functional analysis of the human NF2 tumor suppressor gene in Drosophila.,,NF2,genetic_reagents,Experimental Usage,PUB7332362a,c732c818-394c-51d3-99d5-c960a3514166,USE8f87f160
PMID:40225167,10.1155/2023/9628049,Functional Assays Combined with Pre-mRNA-Splicing Analysis Improve Variant Classification and Diagnostics for Individuals with Neurofibromatosis Type 1 and Legius Syndrome.,,SPRED1,genetic_reagents,Experimental Usage,PUB40225167,c97c2874-6530-5a9f-be63-3228031d0f39,USE7e985367
PMID:32461556 | PMID:38481529 | PMID:39890807 | PMID:34646065 | PMID:37446790 | PMID:34011935 | PMID:29670214 | PMID:37140985 | PMID:36241865,10.1038/s41467-020-16432-0 | 10.3389/fcell.2024.1359561 | 10.1038/s41598-024-84493-y | 10.1155/2021/9386823 | 10.3390/molecules28135128 | 10.1038/s41419-021-03802-9 | 10.1038/s41598-018-24310-5 | 10.1172/JCI168227 | 10.1038/s12276-022-00850-9,Assessing the origin of high-grade serous ovarian cancer using CRISPR-modification of mouse organoids. | Generation of heterozygous and homozygous NF1 lines from human-induced pluripotent stem cells using CRISPR/Cas9 to investigate bone defects associated with neurofibromatosis type 1. | Global proteomics and affinity mass spectrometry analysis of human Schwann cells indicates that variation in and loss of neurofibromin (NF1) alters protein expression and cellular and mitochondrial metabolism. | Survival and | Icariin Promotes Osteogenic Differentiation in a Cell Model with NF1 Gene Knockout by Activating the cAMP/PKA/CREB Pathway. | Metalloproteinase 1 downregulation in neurofibromatosis 1: Therapeutic potential of antimalarial hydroxychloroquine and chloroquine. | Restoring functional neurofibromin by protein transduction. | Basement membrane proteins in extracellular matrix characterize NF1 neurofibroma development and response to MEK inhibitor. | Transplanting neurofibromatosis-1 gene knockout neural stem cells improve functional recovery in rats with spinal cord injury by enhancing the mTORC2 pathway.,,Nf1,genetic_reagents,Experimental Usage,PUB01669d95,182aad93-5fa7-51dc-b298-2c359c28371f,USE2bd316c5
PMID:32457840,10.3389/fonc.2020.00687,"TGFβ Signaling Increases Net Acid Extrusion, Proliferation and Invasion in Panc-1 Pancreatic Cancer Cells: SMAD4 Dependence and Link to Merlin/NF2 Signaling.",,Merlin,genetic_reagents,Experimental Usage,PUB32457840,83ecd84b-4ddc-52b4-9b65-26baf7f4e30d,USE90bdb38d
PMID:39129390,10.1002/1878-0261.13704,Inhibition of autophagy as a novel treatment for neurofibromatosis type 1 tumors.,,dNf1,genetic_reagents,Experimental Usage,PUB39129390,6a54cddc-272f-5cfc-b063-48f9969606ab,USEf1fa606e
PMID:24509877 | PMID:35393510 | PMID:16835260 | PMID:38000020,10.1038/onc.2013.506 | 10.1038/s41418-022-00991-4 | 10.1093/hmg/ddl165 | 10.1126/sciadv.adg8876,MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. | Tumor growth of neurofibromin-deficient cells is driven by decreased respiration and hampered by NAD | Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,NF1-GRD,genetic_reagents,Experimental Usage,PUB5de229dd,e38aa0ec-2c20-56e8-a848-a9dc9af01121,USEa0c1f278
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1-targeting TALEN,genetic_reagents,Experimental Usage,PUB37520682,47c4dd20-2b55-5df4-8b68-67057a9b3504,USE3186b6ad
PMID:37520682,10.1016/j.omtn.2023.06.018,Combining nonsense mutation suppression therapy with nonsense-mediated decay inhibition in neurofibromatosis type 1.,,NF1 DLR,genetic_reagents,Experimental Usage,PUB37520682,01acf277-b66a-501f-9790-86b8b22e9a4a,USEcfa1dec4
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 flox,genetic_reagents,Experimental Usage,PUB22901811,fce11210-d4af-59a8-9332-478ee203fab0,USE8feefad9
PMID:22901811,10.1016/j.cell.2012.06.034,ERK inhibition rescues defects in fate specification of Nf1-deficient neural progenitors and brain abnormalities.,,Nf1 KO,genetic_reagents,Experimental Usage,PUB22901811,9eac762d-fe39-5dd6-92f3-8ef4b951e1c2,USEa913495c
PMID:40590220,10.1172/JCI188932,A haploinsufficiency restoration strategy corrects neurobehavioral deficits in Nf1+/- mice.,,human neurofibromin,genetic_reagents,Experimental Usage,PUB40590220,2af24a58-4a08-5f34-b39a-00372f6d22a8,USE00e1c30f
PMID:27999334,10.3390/genes7120133,Hybridization Capture-Based Next-Generation Sequencing to Evaluate Coding Sequence and Deep Intronic Mutations in the NF1 Gene.,,NF1 capture probes,genetic_reagents,Experimental Usage,PUB27999334,6aef8f45-05fd-54b2-a19a-73f1688f586e,USE3754d4f7
PMID:20195187,10.1097/MAO.0b013e3181d2777f,Merlin knockdown in human Schwann cells: clues to vestibular schwannoma tumorigenesis.,,neurofibromin 2,genetic_reagents,Experimental Usage,PUB20195187,a7926f94-fdf4-5cc2-8b55-e3a892f2de94,USE06646844
PMID:30274821,10.1016/j.ebiom.2018.09.042,Synergistic effect of Nutlin-3 combined with MG-132 on schwannoma cells through restoration of merlin and p53 tumour suppressors.,,NF2 shRNA,genetic_reagents,Experimental Usage,PUB30274821,cb62b06d-517e-5577-b058-c6dc50f63e15,USEb00bc68a
PMID:28831766,10.1007/s12104-017-9768-1,NMR resonance assignments of the EVH1 domain of neurofibromin's recruitment factor Spred1.,,Spred1(EVH1),genetic_reagents,Experimental Usage,PUB28831766,9762d0c4-3a1e-5b5f-bcb2-68b7de13fc26,USE3e31d8bf
PMID:18974932,10.1007/s11060-008-9721-3,A role for the p53 pathway in the pathology of meningiomas with NF2 loss.,,NF2 TET,genetic_reagents,Experimental Usage,PUB18974932,31ce5396-5fef-5952-973a-b36931af7123,USE83ba05b6
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Merlin isoform 1,genetic_reagents,Experimental Usage,PUB24882693,58f25ef1-d11b-59e3-9649-436ff28ce3e7,USE320f9c20
PMID:24882693,10.1016/j.jmb.2014.05.011,Molecular conformation of the full-length tumor suppressor NF2/Merlin--a small-angle neutron scattering study.,,Merlin(S518D) and Merlin(S518E) mutants,genetic_reagents,Experimental Usage,PUB24882693,35b70a2e-944e-5366-90e3-312dccf7dd9b,USE18ab2e9a
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,Merlin siRNA,genetic_reagents,Experimental Usage,PUB25043298,cbc093da-7e68-5b32-818b-f5c9fa24b551,USE830c0184
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,HA-Merlin,genetic_reagents,Experimental Usage,PUB25043298,e27b27fb-155e-5921-902e-5e9db24a264a,USEb485833f
PMID:25043298,10.1038/onc.2014.185,Oncogenic role of Merlin/NF2 in glioblastoma.,,S518A HA-Merlin,genetic_reagents,Experimental Usage,PUB25043298,f650c0fa-4167-5038-a70d-c72ac33d2495,USEf471b8ec
PMID:39415595,10.1242/dmm.050862,Generation of a zebrafish neurofibromatosis model via inducible knockout of nf2a/b.,,nf2a/b-4sgRNA,genetic_reagents,Experimental Usage,PUB39415595,6f302b53-8c6e-5217-b02e-577bc50d14fe,USE8b7fe087
PMID:16835260,10.1093/hmg/ddl165,Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.,,1276P NF1 GRD,genetic_reagents,Experimental Usage,PUB16835260,7efb0f81-781b-508c-8b51-bd1bc42050d0,USE94620d73
PMID:37410426,10.1158/1078-0432.CCR-23-0749,"CDK4/6-MEK Inhibition in MPNSTs Causes Plasma Cell Infiltration, Sensitization to PD-L1 Blockade, and Tumor Regression.",,Cas9 and sgRNAs targeting Nf1+Cdkn2a,genetic_reagents,Experimental Usage,PUB37410426,3e26c266-237c-50ce-bf42-389a5d88cff1,USEaf0a56af
PMID:41022755 | PMID:38000020 | PMID:33032988,10.1038/s41467-025-63619-4 | 10.1126/sciadv.adg8876 | 10.1158/0008-5472.CAN-20-1365,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2-002,patient_derived_models,Experimental Usage,PUB7f382a9c,a238b29c-bfe1-5abe-9f2e-f019bf145305,USE4078078e
PMID:41022755 | PMID:38000020 | PMID:33032988,10.1038/s41467-025-63619-4 | 10.1126/sciadv.adg8876 | 10.1158/0008-5472.CAN-20-1365,Development of an adeno-associated virus vector for gene replacement therapy of NF1-related tumors. | CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors. | Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,,JH-2-031,patient_derived_models,Experimental Usage,PUB7f382a9c,df878292-d243-5bc5-8fe0-1c11a30decb5,USE6b6aa78e
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,JH-2-079c PDX,patient_derived_models,Experimental Usage,PUB38000020,0ad52ce6-3d08-5eae-afa7-4070c3f917b1,USEfcedb4cb
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-225 PDX,patient_derived_models,Experimental Usage,PUB38000020,8f471752-d637-59f2-9b80-30d1566f673a,USE4b3fc7fb
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-386 PDX,patient_derived_models,Experimental Usage,PUB38000020,18cdb28b-9cef-51f5-b411-2b0939e0724d,USE12745c6d
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,WU-545 PDX,patient_derived_models,Experimental Usage,PUB38000020,457d0b4b-25ae-5a5d-8dfc-f9cc116069aa,USEb6f73454
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,MN-2 PDX,patient_derived_models,Experimental Usage,PUB38000020,eb1ec3b8-3373-56da-811c-35ba7f43da05,USE3e20e56c
PMID:38000020,10.1126/sciadv.adg8876,CDK4/6 inhibition enhances SHP2 inhibitor efficacy and is dependent upon RB function in malignant peripheral nerve sheath tumors.,,MN-3-002 PDX,patient_derived_models,Experimental Usage,PUB38000020,64903d54-1f35-5c00-90d5-9dae1f854021,USE0cb26c19
PMID:41036607,10.1158/1535-7163.MCT-24-1053,Pharmacogenomic Synthetic Lethal Screens Reveal Hidden Vulnerabilities and New Therapeutic Approaches for Treatment of NF1-Associated Tumors.,,Patient-derived xenograft (PDX) MPNST model,patient_derived_models,Experimental Usage,PUB41036607,98820301-8821-5496-8914-0f29af4bac44,USEb415bf6c
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-SP-01 PDOX,patient_derived_models,Experimental Usage,PUB35511749,878e2a16-a7c0-52f0-aae3-604a82662542,USE6a3eda3b
PMID:35511749,10.1158/1535-7163.MCT-21-0947,A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.,,MPNST-NF1-09 PDOX,patient_derived_models,Experimental Usage,PUB35511749,1a1e5f49-9944-5fdc-a2bc-507f5a611d38,USEab54bb06
PMID:18636037,10.1097/MAO.0b013e31817f7398,The ErbB inhibitors trastuzumab and erlotinib inhibit growth of vestibular schwannoma xenografts in nude mice: a preliminary study.,,vestibular schwannoma xenografts,patient_derived_models,Experimental Usage,PUB18636037,05082e19-1068-552d-b41a-8de52c52fc44,USE6908e058
PMID:38744290,10.1016/j.crmeth.2024.100772,A platform for rapid patient-derived cutaneous neurofibroma organoid establishment and screening.,,Cutaneous neurofibroma samples,patient_derived_models,Experimental Usage,PUB38744290,22f0b8cc-5350-5fc3-82cc-8d0db0767a1b,USE89461185
PMID:15240917,10.1155/S1110724304308107,Survival of Human Neurofibroma in Immunodeficient Mice and Initial Results of Therapy With Pirfenidone.,,human neurofibroma xenografts,patient_derived_models,Experimental Usage,PUB15240917,e3eae52e-f08c-50ac-a9cf-1cf261cce77e,USEca810e3b
PMID:33658640,10.1038/s41416-021-01270-8,Exploring transcriptional regulators Ref-1 and STAT3 as therapeutic targets in malignant peripheral nerve sheath tumours.,,RHT-92,patient_derived_models,Experimental Usage,PUB33658640,6a3d4fbb-c8ee-5d95-8b3d-f0b5b3991295,USEcc1c0721
PMID:33032988,10.1158/0008-5472.CAN-20-1365,Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.,2020,NF90.8,patient_derived_models,Experimental Usage,PUB33032988,14e76c31-31f8-5251-91e2-27ee74b3d931,USE000e92c7
